###begin article-title 0
Pharmacological prion protein silencing accelerates central nervous system autoimmune disease via T cell receptor signalling
###end article-title 0
###begin p 1
*These authors contributed equally to this work.
###end p 1
###begin p 2
###xml 260 267 260 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 272 280 272 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 439 446 439 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 963 970 963 970 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 1391 1395 1391 1395 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;11</sub>
###xml 422 437 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1412 1427 <span type="species:ncbi:10090">transgenic mice</span>
The primary biological function of the endogenous cellular prion protein has remained unclear. We investigated its biological function in the generation of cellular immune responses using cellular prion protein gene-specific small interfering ribonucleic acid in vivo and in vitro. Our results were confirmed by blocking cellular prion protein with monovalent antibodies and by using cellular prion protein-deficient and -transgenic mice. In vivo prion protein gene-small interfering ribonucleic acid treatment effects were of limited duration, restricted to secondary lymphoid organs and resulted in a 70% reduction of cellular prion protein expression in leukocytes. Disruption of cellular prion protein signalling augmented antigen-specific activation and proliferation, and enhanced T cell receptor signalling, resulting in zeta-chain-associated protein-70 phosphorylation and nuclear factor of activated T cells/activator protein 1 transcriptional activity. In vivo prion protein gene-small interfering ribonucleic acid treatment promoted T cell differentiation towards pro-inflammatory phenotypes and increased survival of antigen-specific T cells. Cellular prion protein silencing with small interfering ribonucleic acid also resulted in the worsening of actively induced and adoptively transferred experimental autoimmune encephalomyelitis. Finally, treatment of myelin basic protein1-11 T cell receptor transgenic mice with prion protein gene-small interfering ribonucleic acid resulted in spontaneous experimental autoimmune encephalomyelitis. Thus, central nervous system autoimmune disease was modulated at all stages of disease: the generation of the T cell effector response, the elicitation of T effector function and the perpetuation of cellular immune responses. Our findings indicate that cellular prion protein regulates T cell receptor-mediated T cell activation, differentiation and survival. Defects in autoimmunity are restricted to the immune system and not the central nervous system. Our data identify cellular prion protein as a regulator of cellular immunological homoeostasis and suggest cellular prion protein as a novel potential target for therapeutic immunomodulation.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 56 57 56 57 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 147 148 147 148 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 287 288 287 288 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 330 336 330 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 338 342 338 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">1999</xref>
###xml 383 384 383 384 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 412 418 412 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 420 424 420 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">1990</xref>
###xml 434 440 434 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 442 446 442 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">2000</xref>
###xml 454 460 454 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 462 466 462 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">2000</xref>
###xml 471 477 471 477 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 479 483 479 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">2001</xref>
###xml 512 518 512 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 520 524 520 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">2001</xref>
###xml 532 538 532 538 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 540 544 540 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">2006</xref>
###xml 582 583 582 583 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 642 643 642 643 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 738 744 738 744 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 746 750 746 750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">2004</xref>
###xml 807 808 807 808 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 1016 1021 <span type="species:ncbi:9606">human</span>
A physiological function for cellular prion protein (PrPc), a glycophosphatidylinositol-anchored sialoglycoprotein, is still enigmatic. So far, PrPc has mainly been studied in the realm of neurodegenerative diseases, specifically as the substrate for the replicative cycle of prions. PrPc is highly expressed in neurons (DeArmond et al., 1999). However, high expression levels of PrPc in lymphoid cells (Cashman et al., 1990; Antoine et al., 2000; Durig et al., 2000; Li et al., 2001) and myeloid cells (Burthem et al., 2001; Krebs et al., 2006) suggest a biological function of PrPc outside the CNS. The recently reported localization of PrPc in the immunological synapse, and its co-precipitation with the T cell receptor (TCR) (Mattei et al., 2004) prompted us to investigate more closely the role of PrPc in mediating T cell activation and function. The role and function of T cells in neuroinflammation can be paradigmatically examined in experimental autoimmune encephalomyelitis (EAE), an animal model of the human disorder multiple sclerosis.
###end p 4
###begin p 5
###xml 32 36 32 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 150 151 150 151 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 225 226 225 226 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 321 322 321 322 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 346 352 346 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 354 358 354 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">1994</xref>
###xml 391 392 391 392 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 402 408 402 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 410 414 410 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">1996</xref>
###xml 498 499 498 499 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 333 337 <span type="species:ncbi:10090">mice</span>
###xml 368 372 <span type="species:ncbi:10090">mice</span>
Here, we silenced the PrP gene (Prnp) product with small interfering ribonucleic acid (siRNA). We observed a significant and selective decrease of PrPc expression in lymphoid tissue, but not in the CNS. Also, silencing of PrPc resulted in a significant worsening of clinical EAE. This finding was confirmed in genetic PrPc-deficient mice (Manson et al., 1994) whereas mice overexpressing PrPc (Fischer et al., 1996) were relatively resistant to EAE induction. Finally, we were able to show that PrPc silencing in T lymphocytes accounted for the observed clinical effects through enhanced T cell activation, TCR signalling and propagation of T cell differentiation towards proinflammatory T helper cell (Th)-1 and Th17 phenotypes.
###end p 5
###begin title 6
Materials and methods
###end title 6
###begin title 7
Peptides and antibodies
###end title 7
###begin p 8
The siRNAs were purchased as purified duplexes from Dharmacon RNA Technologies:
###end p 8
###begin p 9
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 185 191 185 191 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p35&#8211;55</sub>
###xml 219 225 219 225 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ac1&#8211;11</sub>
###xml 252 260 252 260 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p139&#8211;151</sub>
###xml 281 289 281 289 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p323&#8211;339</sub>
###xml 341 342 341 342 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 814 815 811 812 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 839 845 836 842 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 847 851 844 848 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">1992</xref>
###xml 880 882 877 879 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 979 983 976 980 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c&#8722;/&#8722;</sup>
###xml 1025 1026 1022 1023 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 1116 1122 1113 1119 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 320 326 <span type="species:ncbi:9986">Rabbit</span>
###xml 332 337 <span type="species:ncbi:10090">mouse</span>
###xml 443 449 <span type="species:ncbi:9986">rabbit</span>
###xml 455 460 <span type="species:ncbi:10090">mouse</span>
###xml 473 477 <span type="species:ncbi:9925">goat</span>
###xml 483 488 <span type="species:ncbi:10090">mouse</span>
###xml 512 523 <span type="species:ncbi:3704">horseradish</span>
###xml 544 550 <span type="species:ncbi:9986">rabbit</span>
###xml 555 566 <span type="species:ncbi:3704">horseradish</span>
###xml 641 646 <span type="species:ncbi:10090">mouse</span>
###xml 679 684 <span type="species:ncbi:10090">mouse</span>
###xml 826 830 <span type="species:ncbi:10090">mice</span>
###xml 984 988 <span type="species:ncbi:10090">mice</span>
###xml 1016 1021 <span type="species:ncbi:10090">mouse</span>
Prnp-SiRNA 5'-GUGCACGACUCAAUAdT dT; 3'-dTdTCACGUGCUGACGCAGUUAU-5' and nonsense siRNA 5'-CGAACGAGUACCGUACACUdTdT; 3'-dTdTGCUUGCUCAUGGCAUGUGA-5'. myelin oligodendrocyte glycoprotein (MOG)p35-55, myelin basic protein (MBP)Ac1-11, proteolipid protein (PLP)p139-151 and ovalbumine (OVA)p323-339 were synthesized by S.C. Bio. Rabbit anti-mouse PrPc monoclonal antibody ab52604 was obtained from Abcam Inc. Anti-phosphorylation clone 4G10 (Upstate), rabbit anti-mouse beta-actin, goat anti-mouse Immunoglobulin G (IgG)-horseradish peroxidase and anti-rabbit IgG-horseradish peroxidase were obtained from Santa Cruz Biotechnology, Inc. Hamster anti-mouse CD3 (145-2C11) and hamster anti-mouse CD28 (37.51) monoclonal antibodies were purchased from BD Biosciences. The anti-PrP monoclonal antibody W226 was derived from PrPc-deficient mice (Bueler et al., 1992) immunized with purified PrPSc (Petsch and Stitz, manuscript in preparation). The monoclonal antibody 19C4 was derived from PrPc-/- mice immunized with recombinant mouse PrPc. The single-chain variable fragment was generated from W226 hybridoma (Muller-Schiffmann et al., 2009).
###end p 9
###begin title 10
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice
###end title 10
###begin p 11
###xml 148 155 148 155 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">323&#8211;339</sub>
###xml 401 404 401 404 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 463 469 463 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 471 475 471 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">1994</xref>
###xml 498 504 498 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 506 510 506 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">1996</xref>
###xml 642 646 642 646 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;11</sub>
###xml 18 22 <span type="species:ncbi:10090">mice</span>
###xml 177 181 <span type="species:ncbi:10090">mice</span>
###xml 243 247 <span type="species:ncbi:10090">mice</span>
###xml 405 409 <span type="species:ncbi:10090">mice</span>
###xml 484 488 <span type="species:ncbi:10090">mice</span>
###xml 619 623 <span type="species:ncbi:10090">mice</span>
###xml 736 740 <span type="species:ncbi:10090">mice</span>
C57BL/6 and Sv129 mice (8- to 12-week-old) were bred at the animal-breeding facilities at the Friedrich-Loeffler-Institute in Tubingen, Germany. OVA323-339 TCR transgenic (OT2) mice were purchased at The Jackson Laboratories. SJL/J and B10.PL mice were purchased from the Jackson Laboratory (Bar Harbor) and bred in a barrier animal facility at the University of Texas Southwestern Medical Centre. PrP-/- mice were made available to us by Dr. Jean Manson (Manson et al., 1994). Tga20 mice (Fischer et al., 1996) were made available by Dr Adriano Aguzzi, and bred at the Friedrich Loeffler Institute at Tubingen. B10.PL mice transgenic for MBP1-11-specific TCR were a gift from Dr J. Goverman and Dr J. Lafaille. All protocols involving mice handling were approved by the respective Institutional Animal Care and Use Committee.
###end p 11
###begin title 12
Experimental autoimmune encephalomyelitis
###end title 12
###begin p 13
###xml 113 121 109 117 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p139&#8722;151</sub>
###xml 207 233 203 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Mycobacterium tuberculosis</italic>
###xml 281 287 277 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 289 293 285 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">2002</xref>
###xml 295 299 291 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">2006</xref>
###xml 574 582 570 578 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p139&#8722;151</sub>
###xml 652 656 648 652 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 722 730 718 726 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p139&#8722;151</sub>
###xml 944 948 940 944 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 1067 1073 1063 1069 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 1075 1079 1071 1075 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">2002</xref>
###xml 1081 1085 1077 1081 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">2006</xref>
###xml 50 54 <span type="species:ncbi:10090">mice</span>
###xml 207 239 <span type="species:ncbi:419947">Mycobacterium tuberculosis H37Ra</span>
###xml 347 351 <span type="species:ncbi:10090">mice</span>
###xml 516 520 <span type="species:ncbi:10090">mice</span>
###xml 867 871 <span type="species:ncbi:10090">mice</span>
###xml 921 925 <span type="species:ncbi:10090">mice</span>
###xml 974 978 <span type="species:ncbi:10090">Mice</span>
EAE was induced in 8- to 12-week-old female SJL/J mice by subcutaneous (s.c.) immunization with 100 microg of PLPp139-151, which was dissolved in complete freund's adjuvant containing 4 mg/ml of heat-killed Mycobacterium tuberculosis H37Ra (Difco Laboratories) as described (Stuve et al., 2002, 2006). Immediately thereafter and again 48 h later, mice received an intraperitoneal (i.p.) injection of 400 ng pertussis toxin (Ptx) in 0.2 ml of phosphate buffered saline (PBS). For adoptive transfer experiments, SJL/J mice were sacrificed at Day 10 after immunization with PLPp139-151. Splenocytes and lymph node cells were isolated and transfected with Prnp-siRNA or nonsense-siRNA, and then cultured in the presence of PLPp139-151 and interleukin (IL)-12 for 72 h. Viable cells were counted and 2.5 million T cell blasts were injected i.p. into naive SJL/J recipient mice. At the time of adoptive transfer, the recipient mice were treated with Prnp-siRNA or nonsense-siRNA. Mice were examined daily for clinical signs of EAE and scored as previously described (Stuve et al., 2002, 2006): 0 = no paralysis; 1 = loss of tail tone; 2 = hindlimb weakness; 3 = hindlimb paralysis; 4 = hindlimb and forelimb paralysis; 5 = moribund or dead.
###end p 13
###begin title 14
Histopathology
###end title 14
###begin p 15
###xml 252 255 252 255 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 257 258 257 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 284 285 284 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 833 839 833 839 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 841 845 841 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">2002</xref>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 278 282 <span type="species:ncbi:10090">mice</span>
###xml 547 551 <span type="species:ncbi:10090">mice</span>
Mice were anaesthetized and perfused transcardially with PBS and 4% paraformaldehyde. Brains and spinal cords were dissected and embedded in paraffin. Inflammation was assessed by haematoxylin and eosin staining at Day 29 after disease induction in Prp-/- (n = 6) and wild-type mice (n = 7) and expressed as the mean number of inflammatory infiltrates per spinal cord cross-section (inflammatory index). A minimum of 12 spinal cord cross-sections were examined per animal. Brains and spinal cords of siRNA-treated animals were obtained from three mice with EAE of each experimental group at Day 20 and were evaluated by an examiner, blinded to the treatment status of the animal. Quantitative studies were performed on an average of 12 anatomically matched whole cross-sections of brain and spinal cord as described earlier (Youssef et al., 2002).
###end p 15
###begin title 16
siRNA transfections and treatments
###end title 16
###begin p 17
###xml 4 12 4 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 524 525 516 517 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 769 775 754 760 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ac1&#8211;11</sub>
###xml 860 861 837 838 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 1022 1023 999 1000 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 1082 1088 1059 1065 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ac1&#8211;11</sub>
For in vitro transfection of splenocytes, 2 mul TransIT-TKO transfection reagent (Mirus) was diluted in 50 mul serum-free/antibiotic-free Roswell Park Memorial Institute 1640 media per well. After 10 min incubation at room temperature, 1 mul 40 muM siRNA was added to 52 mul diluted transfection reagent. The siRNAs were incubated with the diluted transfection reagent at room temperature with gentle agitation for 30 min. The siRNAs were then added to the Vbeta8.2 transgenic or B10.PL splenocyte cultures containing 5 x 106 cells in 500 mul media per well of a 24 well plate and incubated for 20 h at 37degreesC. On the following day, the cells were collected and washed with fresh media and then resuspended in 2 ml media and placed back in their original wells. MBPAc1-11 peptide was added at 2 mug/ml. For Valpha2.3/Vbeta8.2 transgenic splenocytes, 2 x 106 splenocytes were placed in each well of a 24 well plate. The transfection protocol was the same, except the cells were placed with wild-type splenocytes (6 x 106 cells/well) that had been irradiated and cultured with MBPAc1-11 after the 24 h transfection.
###end p 17
###begin p 18
###xml 4 11 4 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 35 39 34 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
For in vivo experiments, 50 mug of Prnp-siRNA or nonsense-siRNA were administered intravenously (i.v.) at the time of immunization or the time of disease onset in 100 mul PBS via tail vein injection.
###end p 18
###begin title 19
Immunofluorescence
###end title 19
###begin p 20
###xml 179 186 179 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 244 250 244 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 252 256 252 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">2003</xref>
###xml 6 10 <span type="species:ncbi:10090">mice</span>
###xml 15 19 <span type="species:ncbi:10090">mice</span>
###xml 272 276 <span type="species:ncbi:10090">mice</span>
###xml 427 431 <span type="species:ncbi:10090">mice</span>
Naive mice, or mice that had been actively immunized for EAE, were injected intravenously with Cy3-labelled or DY547-labelled siRNAs. To visualize the fluorochrome-labelled siRNA in situ, tissues were prepared as described earlier (Puttaparthi et al., 2003). Briefly, the mice were sacrificed by injecting them with a lethal dose of sodium pentobarbital (250 mg/kg, i.p.) 24 or 72 h after injection of the siRNA. Anaesthetized mice were perfused transcardially with ice-cold PBS. Spinal cord, brain, liver and kidneys were removed and sectioned transversely at 250 microm intervals. Slices were transferred to Gey's balanced salt solution at room temperature. The slices were transferred onto slides and mounted with Gel/Mount. Slides were viewed with an E800 fluorescent microscope (Nikon Instruments Inc.) using Metamorph software.
###end p 20
###begin title 21
###xml 41 48 41 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
Tracking of siRNA-labelled CD4 + T cells in vivo
###end title 21
###begin p 22
###xml 126 130 121 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 207 215 202 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 236 242 231 237 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ac1&#8211;11</sub>
###xml 337 338 328 329 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 363 364 350 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 73 88 <span type="species:ncbi:10090">transgenic mice</span>
###xml 356 361 <span type="species:ncbi:10090">mouse</span>
###xml 477 481 <span type="species:ncbi:10090">mice</span>
Single cell suspensions of splenocytes obtained from Valpha2.3Vss8.2 TCR transgenic mice were transfected with DY547-labelled Prnp-siRNA or nonsense-siRNA as described in the previous section. After 72 h of in vitro stimulation with MBPAc1-11 (6 microg/ml) and IL-12 (0.5 ng/ml) the cells were collected, washed and resuspended at 5 x 106/200 microl. Each mouse (n = 4/siRNA) received 200 microl of siRNA transfected cells via i.p. injection. Seventy-two hours post injection, mice were euthanized and perfused with cold PBS. Numerous tissues, including the lymph nodes, spleen, lung, liver, brain and spinal cord, were collected, processed and examined for expression of DY547-labelled siRNA by flow cytometry (as described below) and immunofluorescence microscopy (described above).
###end p 22
###begin title 23
CD4 T cell purification
###end title 23
###begin p 24
###xml 9 10 9 10 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 147 148 138 139 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
###xml 71 76 <span type="species:ncbi:10090">mouse</span>
Mouse CD4+ T cells were purified from a bulk spleen population using a mouse CD4 T lymphocyte enrichment set (BD IMagtrade mark). The purity of CD4+ T cells was assessed by flow cytometry and exceeded 95%.
###end p 24
###begin title 25
Proliferation assays
###end title 25
###begin p 26
###xml 128 136 128 136 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p139&#8211;151</sub>
###xml 201 205 201 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 321 322 321 322 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 436 437 436 437 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">l</sc>
###xml 590 592 590 592 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;5</sup>
###xml 740 741 736 737 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 91 95 <span type="species:ncbi:10090">mice</span>
###xml 627 632 <span type="species:ncbi:10090">mouse</span>
For primary proliferation assays, splenocytes or lymph node cells were isolated from SJL/J mice that had been immunized with PLPp139-151 seven days before, and that had been concomitantly treated with Prnp-siRNA or nonsense-siRNA. Cells were cultured with antigen in 96 well microtitre plates at a concentration of 5 x 106 cells/ml. Culture medium consisted of Roswell Park Memorial Institute medium 1640 (Invitrogen) supplemented with l-glutamine (2 mM), sodium pyruvate (1 mM), non-essential amino acids (0.1 mM), penicillin (100 U/ml), streptomycin (0.1 mg/ml), 2-mercaptoethanol (5 x 10-5 M) and 1% (v/v) autologous normal mouse serum. Splenocytes were incubated for 72 h. Cultures were then pulsed for 18 h with 1 microCi per well of [3H]thymidine before harvesting. Results are shown as mean of triplicates +/- SEM.
###end p 26
###begin p 27
###xml 110 116 110 116 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ac1&#8211;11</sub>
###xml 135 136 135 136 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 211 217 211 217 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ac1&#8211;11</sub>
###xml 301 305 301 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 404 405 404 405 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 456 457 456 457 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 534 535 534 535 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 591 597 591 597 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ac1&#8211;11</sub>
###xml 690 696 690 696 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">methyl</italic>
###xml 697 698 697 698 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 222 237 <span type="species:ncbi:10090">transgenic mice</span>
###xml 395 400 <span type="species:ncbi:10090">mouse</span>
###xml 525 530 <span type="species:ncbi:10090">mouse</span>
For proliferation assays in which irradiated B10.PL splenocytes served as the antigen presenting cell, and MBPAc1-11 TCR transgenic CD4+-enriched T cells served as effector cells, splenocytes from B10.PL and MBPAc1-11 TCR transgenic mice were brought into single cell suspension, and transfected with Prnp-siRNA or nonsense-siRNA. In other experiments, cells were treated for 24 h with the anti-mouse PrPc monoclonal antibodies 19C4 or W226, or an anti-PrPc single-chain variable fragment and the appropriate isotype control mouse IgG1. Cells were then washed, irradiated and pulsed with MBPAc1-11. Cells were harvested on glass filters using a Tomtec harvester (Tomtec), and incorporated [methyl-3H]thymidine was measured with a Betaplate counter (PerkinElmer).
###end p 27
###begin title 28
Cytokine analysis
###end title 28
###begin p 29
###xml 425 426 421 422 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8217;</bold>
Supernatants from splenocytes cultured in parallel with those cells used in proliferation assays were used for cytokine analysis. Supernatants were collected for interleukin (IL)-2 (48 h), interferon gamma (IFNgamma) and IL-17 (72 h), IL-4, IL-5 and IL-10 (120 h). Quantitative enzyme-linked immunosorbent assay (ELISA) was performed using paired monoclonal antibodies specific for corresponding cytokines as per manufacturer's recommendations (BD PharMingen). The results of ELISA experiments are expressed as an average of triplicate wells +/- SD. A SOFTmax ELISA plate reader and software was used for data analysis (Molecular Devices).
###end p 29
###begin title 30
Western blotting
###end title 30
###begin p 31
###xml 1483 1484 1483 1484 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 301 305 <span type="species:ncbi:10090">mice</span>
Splenocytes were transfected as described above. For preparation of total cell lysates, cells were collected, spun down and resuspended in sodium dodecyl sulfate-lysis buffer. Cells were lysed on ice for 30 min and spun down to remove cell debris. Total cell lysates were also made from the brains of mice using a tissue homogenizer and lysing with sodium dodecyl sulfate-lysis buffer. Protease inhibitors (aprotinin, leupeptin and pepstatin) were added to all lysates at the time of preparation. Prior to the western blot, the protein concentration of these extracts was determined by using the BioRad Protein Assay. The extracts were diluted in sodium dodecyl sulfate loading buffer, boiled for 3 min and were electrophorectically separated on 4-20% sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels. After transfer of the gels to nitrocellulose membranes, the membranes were blocked with 5% milk in tris-buffered saline. The primary antibody was diluted 1:1000 in blocking buffer and was added to the membrane for 2 h. The membrane was washed three times in tris-buffered saline/Tween. The secondary antibody was diluted 1:1000 and was added to the membrane for 1 h. The membrane was washed three times and a chemiluminescent substrate (Bio-rad Inc.) was added for 1 min; the blot was then exposed to film for various times (0.05-10 min). The density of the bands was determined by using ImageQuant 5.2 program. Data were normalized by dividing the density of the PrPc band by the density of the beta-actin band. The data are representative of at least five independent experiments. It is difficult to normalize between experiments, therefore, no error bars are shown.
###end p 31
###begin title 32
Flow cytometry
###end title 32
###begin p 33
###xml 36 41 <span type="species:ncbi:10090">mouse</span>
###xml 47 52 <span type="species:ncbi:10090">mouse</span>
###xml 112 117 <span type="species:ncbi:10090">mouse</span>
###xml 203 208 <span type="species:ncbi:10090">Mouse</span>
###xml 440 444 <span type="species:ncbi:9913">calf</span>
###xml 706 709 <span type="species:ncbi:10116">rat</span>
###xml 715 720 <span type="species:ncbi:10090">mouse</span>
###xml 775 780 <span type="species:ncbi:10090">mouse</span>
The following antibodies were used: mouse anti-mouse PrP antibody (W226), fluorescein isothiocyanate-conjugated mouse IgG1 (BD Biosciences) and antigen presenting cell-conjugated anti-CD3 (eBioscience). Mouse spleens were pressed through a 70 microm nylon mesh cell strainer. Then, splenocytes were treated with RBC lysing buffer (Sigma-Aldrich). For flow cytometry, cells were counted, washed and resuspended in staining buffer (4% foetal calf serum and 0.1% sodium azide in PBS). Fc receptors were blocked with anti-CD16/32 (BD Biosciences) and the cells were incubated with 1 microg W226 monoclonal antibody for 45 min at 4degreesC. W226 staining was revealed with fluorescein isothiocyanate conjugated rat anti-mouse IgG1 followed by a 30 min blocking step with purified mouse immunoglobulins. After washing twice with staining buffer, cells were stained with directly labelled anti-CD3 for 30 min on ice, washed and then fixed with 1% paraformaldehyde. Twenty thousand gated events were acquired on a FACSCalibur (BD Biosciences) and analysed using FlowJo software (Tree Star).
###end p 33
###begin title 34
Phosphorylation assay
###end title 34
###begin p 35
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 119 123 <span type="species:ncbi:9925">goat</span>
CD4+ T cells were activated by suspending cells in media with biotinylated anti-CD3 antibody (5 microg/ml) for 20 min, goat anti-hamster IgG (10 microg/ml Jackson Immunoresearch) for 1 min and then treated with anti-CD28 for 1 and 5 min, respectively. Sodium orthovanadate was then added to stop the phosphorylation and western blot analysis was performed.
###end p 35
###begin title 36
T cells activation assays
###end title 36
###begin p 37
###xml 53 59 53 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 61 65 61 65 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">1983</xref>
###xml 170 176 170 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 178 182 178 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">2004</xref>
###xml 267 273 267 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 275 279 275 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">2005</xref>
###xml 668 674 665 671 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 676 680 673 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">2001</xref>
###xml 953 959 <span type="species:ncbi:10090">murine</span>
A fast-growing variant of the D10 T cell clone (Kaye et al., 1983) was obtained from M. Krummel (University of California, San Francisco) and cultured as described (Kane et al., 2004). D10 cells (15 million) were transfected by electroporation as described (de Souza et al., 2005). For luciferase assays, cells were resuspended 18-20 h later at 2 million/ml in fresh media and stimulated for 6 h with biotinylated anti-CD3 and anti-CD28 antibodies (1 mug/ml each; BD Biosciences) plus streptavidin (5 mug/ml; Zymed) or phorbol 12-myristate 13-acetate (PMA) (25 ng/ml; Calbiochem) plus ionomycin (1 mum; Sigma). Luciferase activity was then measured as described (Kane et al., 2001). For determination of activation markers, cells were re-suspended the day after transfection at 1 million/ml and stimulated for 18 h with either media alone or anti-CD3/CD28 antibodies at 1 mug/ml each. Cells were then stained with phycoerythrin-conjugated antibodies to murine CD25 or CD69 (Caltag) and analysed on a BD LSR II flow cytometer.
###end p 37
###begin title 38
Statistical analysis
###end title 38
###begin p 39
###xml 176 177 176 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 312 313 312 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Correlations between continuous and categorical variables were assessed using the Mann-Whitney U-test. The means of two normally distributed samples were compared by Student's t-test. All other statistical comparisons between groups were examined using one-way multiple range ANOVA test for multiple comparison. P-values <0.05 were considered significant.
###end p 39
###begin title 40
Results
###end title 40
###begin title 41
###xml 27 28 27 28 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 82 83 82 83 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
Peripheral silencing of PrPC with siRNA does not affect central nervous system PrPC expression
###end title 41
###begin p 42
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 102 103 102 103 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 209 217 209 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 258 262 258 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 296 297 296 297 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 310 316 310 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 335 342 335 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 386 392 386 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 444 448 443 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 456 462 455 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 469 470 468 469 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 534 540 533 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 581 582 580 581 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 646 647 633 634 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 661 665 648 652 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 765 771 752 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 813 817 800 804 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 1096 1102 1083 1089 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 1158 1164 1145 1151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 1215 1219 1202 1206 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 1293 1294 1280 1281 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 1348 1349 1335 1336 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 1372 1380 1359 1367 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1</label>
###xml 1394 1395 1381 1382 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 1479 1483 1466 1470 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 1492 1493 1479 1480 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 1513 1517 1500 1504 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 1537 1538 1524 1525 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 1633 1640 1620 1627 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1655 1656 1642 1643 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 1686 1687 1673 1674 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1718 1726 1705 1713 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p139&#8722;151</sub>
###xml 1742 1746 1728 1732 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 1757 1758 1743 1744 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 1812 1813 1798 1799 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 1852 1855 1838 1841 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A&#8211;D</bold>
###xml 1901 1902 1887 1888 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 1951 1952 1937 1938 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 1976 1977 1959 1960 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 2115 2116 2098 2099 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 2163 2165 2146 2148 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c+</sup>
###xml 2186 2187 2169 2170 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2293 2295 2276 2278 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c+</sup>
###xml 2316 2317 2299 2300 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2339 2343 2322 2326 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 2375 2376 2358 2359 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 2432 2436 2403 2407 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 2455 2456 2426 2427 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
###xml 1380 2711 1367 2682 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="43"> Decreased PrP<sup>c</sup> expression levels on peripheral leucocytes but not in the CNS in mice treated with <italic>Prnp</italic>-siRNA. (<bold>A</bold>) Transfection with <italic>Prnp</italic>-siRNA decreased PrP<sup>c</sup> expression in murine splenocytes, compared with nonsense (NS)-siRNA treatment. On Day 3 after <italic>in vivo</italic> treatment of (<bold>B</bold>) unimmunized SJL/J mice and (<bold>C</bold>) SJL/J mice immunized with PLP<sub>p139&#8722;151</sub> with 50 &#956;g of <italic>Prnp</italic>-siRNA, PrP<sup>c</sup> expression was decreased in splenocytes, but not in (<bold>D</bold>) brain homogenate of immunized mice. (<bold>A&#8211;D</bold>) Densitometry was performed, and relative PrP<sup>c</sup> expression was determined by normalizing the PrP<sup>c</sup> to &#946;-actin levels. (<bold>E</bold>) Using flow cytometry three days after immunization and siRNA treatment, lymph node cells (LNC) and splenocytes were gated on CD3 and PrP<sup>c</sup>. The top two panels show the percentage of PrP<sup>c+</sup> cells within the CD3<sup>+</sup> cell population from nonsense-siRNA-treated murine cells. The lower two panels show the percentage of PrP<sup>c+</sup> cells within the CD3<sup>+</sup> cell population from <italic>Prnp</italic>-siRNA-treated murine cells. PrP<sup>c</sup> expression was decreased by &#8764;70% following <italic>Prnp</italic>-siRNA treatment. (<bold>F</bold>) After injecting Cy3-labelled siRNA or DY547-labelled siRNA intravenously, fluorescence was detectable 72 h later in liver and kidney tissue but not in the brain of na&#239;ve mice or mice in which EAE had been induced by active immunization (data not shown).</p>
###xml 1380 2711 1367 2682 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="43"> Decreased PrP<sup>c</sup> expression levels on peripheral leucocytes but not in the CNS in mice treated with <italic>Prnp</italic>-siRNA. (<bold>A</bold>) Transfection with <italic>Prnp</italic>-siRNA decreased PrP<sup>c</sup> expression in murine splenocytes, compared with nonsense (NS)-siRNA treatment. On Day 3 after <italic>in vivo</italic> treatment of (<bold>B</bold>) unimmunized SJL/J mice and (<bold>C</bold>) SJL/J mice immunized with PLP<sub>p139&#8722;151</sub> with 50 &#956;g of <italic>Prnp</italic>-siRNA, PrP<sup>c</sup> expression was decreased in splenocytes, but not in (<bold>D</bold>) brain homogenate of immunized mice. (<bold>A&#8211;D</bold>) Densitometry was performed, and relative PrP<sup>c</sup> expression was determined by normalizing the PrP<sup>c</sup> to &#946;-actin levels. (<bold>E</bold>) Using flow cytometry three days after immunization and siRNA treatment, lymph node cells (LNC) and splenocytes were gated on CD3 and PrP<sup>c</sup>. The top two panels show the percentage of PrP<sup>c+</sup> cells within the CD3<sup>+</sup> cell population from nonsense-siRNA-treated murine cells. The lower two panels show the percentage of PrP<sup>c+</sup> cells within the CD3<sup>+</sup> cell population from <italic>Prnp</italic>-siRNA-treated murine cells. PrP<sup>c</sup> expression was decreased by &#8764;70% following <italic>Prnp</italic>-siRNA treatment. (<bold>F</bold>) After injecting Cy3-labelled siRNA or DY547-labelled siRNA intravenously, fluorescence was detectable 72 h later in liver and kidney tissue but not in the brain of na&#239;ve mice or mice in which EAE had been induced by active immunization (data not shown).</p></caption>
###xml 2711 2711 2682 2682 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="awp298f1"/>
###xml 1372 2711 1359 2682 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F1" position="float"><label>Figure 1</label><caption><p textid="43"> Decreased PrP<sup>c</sup> expression levels on peripheral leucocytes but not in the CNS in mice treated with <italic>Prnp</italic>-siRNA. (<bold>A</bold>) Transfection with <italic>Prnp</italic>-siRNA decreased PrP<sup>c</sup> expression in murine splenocytes, compared with nonsense (NS)-siRNA treatment. On Day 3 after <italic>in vivo</italic> treatment of (<bold>B</bold>) unimmunized SJL/J mice and (<bold>C</bold>) SJL/J mice immunized with PLP<sub>p139&#8722;151</sub> with 50 &#956;g of <italic>Prnp</italic>-siRNA, PrP<sup>c</sup> expression was decreased in splenocytes, but not in (<bold>D</bold>) brain homogenate of immunized mice. (<bold>A&#8211;D</bold>) Densitometry was performed, and relative PrP<sup>c</sup> expression was determined by normalizing the PrP<sup>c</sup> to &#946;-actin levels. (<bold>E</bold>) Using flow cytometry three days after immunization and siRNA treatment, lymph node cells (LNC) and splenocytes were gated on CD3 and PrP<sup>c</sup>. The top two panels show the percentage of PrP<sup>c+</sup> cells within the CD3<sup>+</sup> cell population from nonsense-siRNA-treated murine cells. The lower two panels show the percentage of PrP<sup>c+</sup> cells within the CD3<sup>+</sup> cell population from <italic>Prnp</italic>-siRNA-treated murine cells. PrP<sup>c</sup> expression was decreased by &#8764;70% following <italic>Prnp</italic>-siRNA treatment. (<bold>F</bold>) After injecting Cy3-labelled siRNA or DY547-labelled siRNA intravenously, fluorescence was detectable 72 h later in liver and kidney tissue but not in the brain of na&#239;ve mice or mice in which EAE had been induced by active immunization (data not shown).</p></caption><graphic xlink:href="awp298f1"/></fig>
###xml 234 240 <span type="species:ncbi:10090">murine</span>
###xml 380 384 <span type="species:ncbi:10090">mice</span>
###xml 406 410 <span type="species:ncbi:10090">mice</span>
###xml 680 685 <span type="species:ncbi:10090">mouse</span>
###xml 944 948 <span type="species:ncbi:10090">mice</span>
###xml 1152 1156 <span type="species:ncbi:10090">mice</span>
###xml 1170 1174 <span type="species:ncbi:10090">mice</span>
###xml 1253 1257 <span type="species:ncbi:10090">mice</span>
###xml 1461 1465 <span type="species:ncbi:10090">mice</span>
###xml 1553 1559 <span type="species:ncbi:10090">murine</span>
###xml 1676 1680 <span type="species:ncbi:10090">mice</span>
###xml 1695 1699 <span type="species:ncbi:10090">mice</span>
###xml 1845 1849 <span type="species:ncbi:10090">mice</span>
###xml 2232 2238 <span type="species:ncbi:10090">murine</span>
###xml 2358 2364 <span type="species:ncbi:10090">murine</span>
###xml 2628 2632 <span type="species:ncbi:10090">mice</span>
###xml 2636 2640 <span type="species:ncbi:10090">mice</span>
Prnp-specific siRNA and control NS-siRNA were generated to investigate the tissue specific role of PrPc in activating and perpetuating cellular immune responses. By western blot analyses, we demonstrated that in vitro transfection of murine splenocytes with Prnp-siRNA substantially decreased PrPc expression (Fig. 1A). On Day 3 after in vivo intravenous treatment of naive SJL/J mice (Fig. 1B), and SJL/J mice immunized for EAE with 50 mug of Prnp-siRNA (Fig. 1C), PrPc expression was decreased in splenocytes, but not in the brain (Fig. 1D). When evaluated by flow cytometry, PrPc expression was found to be decreased by approximately70% in CD3+ T cells from Prnp-siRNA-treated mouse lymph node cells and splenocytes compared with nonsense-siRNA-treated samples (Fig. 1E). To investigate the bioavailability of Prnp-siRNA further, Cy3-labelled siRNA or DY547-labelled siRNA was injected intravenously into naive experimental animals, or into mice in which EAE had been induced by active immunization. Fluorescence was detectable in the tissue sections of liver and kidney 72 h after injection (Fig. 1F), but not in the brain and spinal cord of naive mice (Fig. 1F) or mice with active EAE (data not shown). Thus, Prnp-siRNA treatment created chimeric mice that expressed normal levels of PrPc in the CNS, but substantially decreased levels of PrPc in peripheral organs. Figure 1 Decreased PrPc expression levels on peripheral leucocytes but not in the CNS in mice treated with Prnp-siRNA. (A) Transfection with Prnp-siRNA decreased PrPc expression in murine splenocytes, compared with nonsense (NS)-siRNA treatment. On Day 3 after in vivo treatment of (B) unimmunized SJL/J mice and (C) SJL/J mice immunized with PLPp139-151 with 50 mug of Prnp-siRNA, PrPc expression was decreased in splenocytes, but not in (D) brain homogenate of immunized mice. (A-D) Densitometry was performed, and relative PrPc expression was determined by normalizing the PrPc to beta-actin levels. (E) Using flow cytometry three days after immunization and siRNA treatment, lymph node cells (LNC) and splenocytes were gated on CD3 and PrPc. The top two panels show the percentage of PrPc+ cells within the CD3+ cell population from nonsense-siRNA-treated murine cells. The lower two panels show the percentage of PrPc+ cells within the CD3+ cell population from Prnp-siRNA-treated murine cells. PrPc expression was decreased by approximately70% following Prnp-siRNA treatment. (F) After injecting Cy3-labelled siRNA or DY547-labelled siRNA intravenously, fluorescence was detectable 72 h later in liver and kidney tissue but not in the brain of naive mice or mice in which EAE had been induced by active immunization (data not shown).
###end p 42
###begin p 43
###xml 14 15 14 15 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 99 103 99 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 112 113 112 113 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 133 137 133 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 157 158 157 158 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 253 260 253 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 275 276 275 276 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 306 307 306 307 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 338 346 338 346 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p139&#8722;151</sub>
###xml 362 366 361 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 377 378 376 377 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 432 433 431 432 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 472 475 471 474 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A&#8211;D</bold>
###xml 521 522 520 521 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 571 572 570 571 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 596 597 592 593 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 735 736 731 732 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 783 785 779 781 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c+</sup>
###xml 806 807 802 803 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 913 915 909 911 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c+</sup>
###xml 936 937 932 933 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 959 963 955 959 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 995 996 991 992 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 1052 1056 1036 1040 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 1075 1076 1059 1060 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
###xml 81 85 <span type="species:ncbi:10090">mice</span>
###xml 173 179 <span type="species:ncbi:10090">murine</span>
###xml 296 300 <span type="species:ncbi:10090">mice</span>
###xml 315 319 <span type="species:ncbi:10090">mice</span>
###xml 465 469 <span type="species:ncbi:10090">mice</span>
###xml 852 858 <span type="species:ncbi:10090">murine</span>
###xml 978 984 <span type="species:ncbi:10090">murine</span>
###xml 1248 1252 <span type="species:ncbi:10090">mice</span>
###xml 1256 1260 <span type="species:ncbi:10090">mice</span>
 Decreased PrPc expression levels on peripheral leucocytes but not in the CNS in mice treated with Prnp-siRNA. (A) Transfection with Prnp-siRNA decreased PrPc expression in murine splenocytes, compared with nonsense (NS)-siRNA treatment. On Day 3 after in vivo treatment of (B) unimmunized SJL/J mice and (C) SJL/J mice immunized with PLPp139-151 with 50 mug of Prnp-siRNA, PrPc expression was decreased in splenocytes, but not in (D) brain homogenate of immunized mice. (A-D) Densitometry was performed, and relative PrPc expression was determined by normalizing the PrPc to beta-actin levels. (E) Using flow cytometry three days after immunization and siRNA treatment, lymph node cells (LNC) and splenocytes were gated on CD3 and PrPc. The top two panels show the percentage of PrPc+ cells within the CD3+ cell population from nonsense-siRNA-treated murine cells. The lower two panels show the percentage of PrPc+ cells within the CD3+ cell population from Prnp-siRNA-treated murine cells. PrPc expression was decreased by approximately70% following Prnp-siRNA treatment. (F) After injecting Cy3-labelled siRNA or DY547-labelled siRNA intravenously, fluorescence was detectable 72 h later in liver and kidney tissue but not in the brain of naive mice or mice in which EAE had been induced by active immunization (data not shown).
###end p 43
###begin title 44
###xml 13 14 13 14 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
Silencing PrPc with siRNA worsens clinical and neuropathological central nervous system autoimmune disease
###end title 44
###begin p 45
###xml 23 24 23 24 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 113 121 113 121 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p139&#8722;151</sub>
###xml 147 151 146 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 272 278 270 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 280 284 278 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">2004</xref>
###xml 389 393 387 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 542 548 540 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2</xref>
###xml 617 621 615 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 777 783 775 781 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2</xref>
###xml 789 797 787 795 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2</label>
###xml 797 801 795 799 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 838 841 836 839 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 903 904 901 902 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 921 922 919 920 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 927 928 925 926 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 930 937 928 935 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 954 955 952 953 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 1024 1025 1022 1023 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 1123 1127 1121 1125 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 1193 1201 1191 1199 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p139&#8722;151</sub>
###xml 1233 1237 1231 1235 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 1299 1300 1297 1298 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 1336 1340 1334 1338 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 1447 1451 1445 1449 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 1516 1517 1514 1515 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1529 1530 1527 1528 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 1542 1545 1540 1543 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1649 1650 1647 1648 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 797 1765 795 1763 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="46"><italic>Prnp</italic>-siRNA treated and PrP-deficient (PrP<sup>&#8722;/&#8722;</sup>) mice develop more severe EAE whereas mice overexpressing PrP<sup>C</sup> are protected. (<bold>A</bold> and <bold>B</bold>) <italic>In vivo</italic> silencing of PrP<sup>c</sup> worsens the clinical course of actively induced EAE in SJL/J mice. (<bold>A</bold>) In an EAE &#8216;prevention&#8217; experiment, SJL/L mice were injected intravenously with a single dose of <italic>Prnp</italic>-siRNA or nonsense (NS)-siRNA at the time of immunization with PLP<sub>p139&#8722;151</sub>, as indicated by a grey arrow. <italic>Prnp</italic>-siRNA treatment resulted in clinically more severe disease. (<bold>B</bold>) In an EAE &#8216;treatment&#8217; experiment, <italic>Prnp</italic>-siRNA or nonsense-siRNA was injected at the time of clinical onset of EAE (grey arrow). Mice treated with <italic>Prnp</italic>-siRNA had a significantly worse initial clinical exacerbation. (<bold>C</bold>) Male and (<bold>D</bold>) female PrP<sup>&#8722;/&#8722;</sup> mice had earlier disease onset and significantly higher disease scores than male wild-type (WT) mice. (<bold>E</bold>) Tga20 mice had a delayed disease onset, and developed only mild EAE compared to C57BL/6 and Sv129 wild-type mice.</p>
###xml 797 1765 795 1763 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="46"><italic>Prnp</italic>-siRNA treated and PrP-deficient (PrP<sup>&#8722;/&#8722;</sup>) mice develop more severe EAE whereas mice overexpressing PrP<sup>C</sup> are protected. (<bold>A</bold> and <bold>B</bold>) <italic>In vivo</italic> silencing of PrP<sup>c</sup> worsens the clinical course of actively induced EAE in SJL/J mice. (<bold>A</bold>) In an EAE &#8216;prevention&#8217; experiment, SJL/L mice were injected intravenously with a single dose of <italic>Prnp</italic>-siRNA or nonsense (NS)-siRNA at the time of immunization with PLP<sub>p139&#8722;151</sub>, as indicated by a grey arrow. <italic>Prnp</italic>-siRNA treatment resulted in clinically more severe disease. (<bold>B</bold>) In an EAE &#8216;treatment&#8217; experiment, <italic>Prnp</italic>-siRNA or nonsense-siRNA was injected at the time of clinical onset of EAE (grey arrow). Mice treated with <italic>Prnp</italic>-siRNA had a significantly worse initial clinical exacerbation. (<bold>C</bold>) Male and (<bold>D</bold>) female PrP<sup>&#8722;/&#8722;</sup> mice had earlier disease onset and significantly higher disease scores than male wild-type (WT) mice. (<bold>E</bold>) Tga20 mice had a delayed disease onset, and developed only mild EAE compared to C57BL/6 and Sv129 wild-type mice.</p></caption>
###xml 1765 1765 1763 1763 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="awp298f2"/>
###xml 789 1765 787 1763 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F2" position="float"><label>Figure 2</label><caption><p textid="46"><italic>Prnp</italic>-siRNA treated and PrP-deficient (PrP<sup>&#8722;/&#8722;</sup>) mice develop more severe EAE whereas mice overexpressing PrP<sup>C</sup> are protected. (<bold>A</bold> and <bold>B</bold>) <italic>In vivo</italic> silencing of PrP<sup>c</sup> worsens the clinical course of actively induced EAE in SJL/J mice. (<bold>A</bold>) In an EAE &#8216;prevention&#8217; experiment, SJL/L mice were injected intravenously with a single dose of <italic>Prnp</italic>-siRNA or nonsense (NS)-siRNA at the time of immunization with PLP<sub>p139&#8722;151</sub>, as indicated by a grey arrow. <italic>Prnp</italic>-siRNA treatment resulted in clinically more severe disease. (<bold>B</bold>) In an EAE &#8216;treatment&#8217; experiment, <italic>Prnp</italic>-siRNA or nonsense-siRNA was injected at the time of clinical onset of EAE (grey arrow). Mice treated with <italic>Prnp</italic>-siRNA had a significantly worse initial clinical exacerbation. (<bold>C</bold>) Male and (<bold>D</bold>) female PrP<sup>&#8722;/&#8722;</sup> mice had earlier disease onset and significantly higher disease scores than male wild-type (WT) mice. (<bold>E</bold>) Tga20 mice had a delayed disease onset, and developed only mild EAE compared to C57BL/6 and Sv129 wild-type mice.</p></caption><graphic xlink:href="awp298f2"/></fig>
###xml 100 104 <span type="species:ncbi:10090">mice</span>
###xml 599 603 <span type="species:ncbi:10090">mice</span>
###xml 697 701 <span type="species:ncbi:10090">mice</span>
###xml 843 847 <span type="species:ncbi:10090">mice</span>
###xml 880 884 <span type="species:ncbi:10090">mice</span>
###xml 1017 1021 <span type="species:ncbi:10090">mice</span>
###xml 1068 1072 <span type="species:ncbi:10090">mice</span>
###xml 1429 1433 <span type="species:ncbi:10090">Mice</span>
###xml 1546 1550 <span type="species:ncbi:10090">mice</span>
###xml 1642 1646 <span type="species:ncbi:10090">mice</span>
###xml 1658 1662 <span type="species:ncbi:10090">mice</span>
###xml 1760 1764 <span type="species:ncbi:10090">mice</span>
To test the role of PrPc in CNS autoimmune disease, EAE was induced by active immunization of SJL/J mice with PLPp139-151. A single dose of 50 mug Prnp-siRNA or nonsense-siRNA was injected i.v. via the tail vein in 100 mul PBS according to published methods (Lovett-Racke et al., 2004). Experimental animals were monitored for 40 days. In a set of 'prevention' experiments, treatment with Prnp-siRNA resulted in significantly worse clinical EAE within the first 10 days after disease onset than treatment with nonsense-siRNA or no treatment (Fig. 2A, A). In a second set of 'treatment' experiments, mice treated with Prnp-siRNA had a significantly worse initial clinical exacerbation than control mice and continued to do significantly worse throughout the observation period (Fig. 2B, B) Figure 2Prnp-siRNA treated and PrP-deficient (PrP-/-) mice develop more severe EAE whereas mice overexpressing PrPC are protected. (A and B) In vivo silencing of PrPc worsens the clinical course of actively induced EAE in SJL/J mice. (A) In an EAE 'prevention' experiment, SJL/L mice were injected intravenously with a single dose of Prnp-siRNA or nonsense (NS)-siRNA at the time of immunization with PLPp139-151, as indicated by a grey arrow. Prnp-siRNA treatment resulted in clinically more severe disease. (B) In an EAE 'treatment' experiment, Prnp-siRNA or nonsense-siRNA was injected at the time of clinical onset of EAE (grey arrow). Mice treated with Prnp-siRNA had a significantly worse initial clinical exacerbation. (C) Male and (D) female PrP-/- mice had earlier disease onset and significantly higher disease scores than male wild-type (WT) mice. (E) Tga20 mice had a delayed disease onset, and developed only mild EAE compared to C57BL/6 and Sv129 wild-type mice.
###end p 45
###begin p 46
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 41 44 41 44 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 106 107 106 107 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 124 125 124 125 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 130 131 130 131 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 133 140 133 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 157 158 157 158 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 227 228 227 228 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 326 330 326 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 396 404 396 404 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p139&#8722;151</sub>
###xml 436 440 436 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 502 503 502 503 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 539 543 539 543 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 650 654 650 654 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 719 720 719 720 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 732 733 732 733 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 745 748 745 748 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 852 853 852 853 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 46 50 <span type="species:ncbi:10090">mice</span>
###xml 83 87 <span type="species:ncbi:10090">mice</span>
###xml 220 224 <span type="species:ncbi:10090">mice</span>
###xml 271 275 <span type="species:ncbi:10090">mice</span>
###xml 632 636 <span type="species:ncbi:10090">Mice</span>
###xml 749 753 <span type="species:ncbi:10090">mice</span>
###xml 845 849 <span type="species:ncbi:10090">mice</span>
###xml 861 865 <span type="species:ncbi:10090">mice</span>
###xml 963 967 <span type="species:ncbi:10090">mice</span>
Prnp-siRNA treated and PrP-deficient (PrP-/-) mice develop more severe EAE whereas mice overexpressing PrPC are protected. (A and B) In vivo silencing of PrPc worsens the clinical course of actively induced EAE in SJL/J mice. (A) In an EAE 'prevention' experiment, SJL/L mice were injected intravenously with a single dose of Prnp-siRNA or nonsense (NS)-siRNA at the time of immunization with PLPp139-151, as indicated by a grey arrow. Prnp-siRNA treatment resulted in clinically more severe disease. (B) In an EAE 'treatment' experiment, Prnp-siRNA or nonsense-siRNA was injected at the time of clinical onset of EAE (grey arrow). Mice treated with Prnp-siRNA had a significantly worse initial clinical exacerbation. (C) Male and (D) female PrP-/- mice had earlier disease onset and significantly higher disease scores than male wild-type (WT) mice. (E) Tga20 mice had a delayed disease onset, and developed only mild EAE compared to C57BL/6 and Sv129 wild-type mice.
###end p 46
###begin p 47
###xml 160 161 160 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 215 216 215 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 253 257 253 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 364 365 364 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 235 239 <span type="species:ncbi:10090">mice</span>
Histological evaluation of CNS tissue with haematoxylin and eosin (data not shown) revealed a significantly increased number of inflammatory foci in the brain (P = 0.046; data not shown) and spinal cord parenchyma (P = 0.04; D) in EAE mice treated with Prnp-siRNA. In the brain, the difference in inflammatory infiltrates was also significant within the meninges (P = 0.008; data not shown).
###end p 47
###begin p 48
###xml 59 62 59 62 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 76 82 76 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 84 88 84 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">1994</xref>
###xml 167 170 167 170 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 268 274 268 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2</xref>
###xml 302 305 302 305 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 424 430 424 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2</xref>
###xml 567 570 567 570 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 63 67 <span type="species:ncbi:10090">mice</span>
###xml 153 157 <span type="species:ncbi:10090">mice</span>
###xml 171 175 <span type="species:ncbi:10090">mice</span>
###xml 262 266 <span type="species:ncbi:10090">mice</span>
###xml 306 310 <span type="species:ncbi:10090">mice</span>
###xml 386 390 <span type="species:ncbi:10090">mice</span>
###xml 571 575 <span type="species:ncbi:10090">mice</span>
Next, we performed active immunization to induce EAE in PrP-/- mice (Manson et al., 1994) on the Sv129/OLA background (H-2b), and in Sv129/OLA wild-type mice. Male PrP-/- mice had earlier disease onset and significantly higher disease scores than male wild-type mice (Fig. 2C, C). Similarly, female PrP-/- mice had earlier disease onset and worse clinical disease than female wild-type mice over a longer period of 80 days (Fig. 2D, D). Histopathology obtained at Day 29 after disease induction revealed significantly higher numbers of inflammatory infiltrates in PrP-/- mice compared with wild-type controls (A-C).
###end p 48
###begin p 49
###xml 96 100 96 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 145 149 145 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 209 210 204 205 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 251 255 246 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 280 287 275 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 585 586 580 581 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 663 667 658 662 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 78 82 <span type="species:ncbi:10090">mice</span>
To determine whether the increased number of inflammatory cells in the CNS of mice treated with Prnp-siRNA are antigen-specific T cells in which Prnp was silenced, we tracked Valpha2.3Vss8.2 TCR transgenic CD4+ T cells transfected with DY547-labelled Prnp-siRNA or nonsense-siRNA in vivo. Numerous tissues, including the lymph nodes, spleen, lung, liver, brain and spinal cord were collected, processed and examined for expression of DY547-labelled siRNA by flow cytometry and immunofluorescence microscopy. With regard to absolute cell numbers and percent of fluorochrome-labelled CD4+ T cells there was no difference in any of the organs between cells in which Prnp had been silenced, and in those in which it had not been silenced by siRNA (data not shown).
###end p 49
###begin title 50
###xml 23 24 23 24 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice overexpressing PrPc are protected from severe experimental autoimmune encephalomyelitis
###end title 50
###begin p 51
###xml 44 45 44 45 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 55 61 55 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 63 67 63 67 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">1996</xref>
###xml 205 211 205 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2</xref>
###xml 256 262 256 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 264 268 264 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">2009</xref>
###xml 327 328 327 328 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 336 337 336 337 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 620 626 616 622 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 628 632 624 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">2009</xref>
###xml 673 674 669 670 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 6 10 <span type="species:ncbi:10090">mice</span>
###xml 147 151 <span type="species:ncbi:10090">mice</span>
###xml 172 176 <span type="species:ncbi:10090">mice</span>
###xml 369 373 <span type="species:ncbi:10090">mice</span>
###xml 552 557 <span type="species:ncbi:10090">mouse</span>
###xml 608 612 <span type="species:ncbi:10090">mice</span>
###xml 719 723 <span type="species:ncbi:10090">mice</span>
Tga20 mice that ubiquitously overexpress PrPc (Fischer et al., 1996) had a later disease onset and developed milder disease than C57BL/6 wild-type mice and Sv129 wild-type mice that were used as controls (Fig. 2E, E). Consistent with published data (Zabel et al., 2009), we observed a significantly lower absolute number of CD4+ and CD8+ T cells in the spleen of Tga20 mice compared with wild-type controls (data not shown). Other investigators had previously demonstrated that mRNA transcripts from pre-TCR-alpha, a T-cell development gene located on mouse chromosome 17, are substantially reduced in Tga20 mice (Zabel et al., 2009). Interestingly, the percentage of FoxP3+ T regulatory T cells was increased in these mice compared with wild-type controls (data not shown).
###end p 51
###begin title 52
###xml 13 14 13 14 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
Silencing PrPc on antigen-specific T cells promotes the differentiation into Th1 and Th17 phenotypes
###end title 52
###begin p 53
###xml 46 54 46 54 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p139&#8211;151</sub>
###xml 99 103 95 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 219 227 215 223 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p139&#8211;151</sub>
###xml 363 367 355 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 422 428 414 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3</xref>
###xml 450 456 438 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3</xref>
###xml 470 476 458 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3</xref>
###xml 529 530 517 518 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 569 575 557 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3</xref>
###xml 585 591 573 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3</xref>
###xml 605 611 593 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3</xref>
###xml 873 877 853 857 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 928 934 908 914 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3</xref>
###xml 1038 1044 1018 1024 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3</xref>
###xml 1048 1056 1028 1036 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3</label>
###xml 1070 1071 1050 1051 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 1244 1252 1224 1232 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p139&#8211;151</sub>
###xml 1311 1315 1287 1291 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 1437 1445 1413 1421 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p139&#8211;151</sub>
###xml 1578 1579 1550 1551 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 1623 1624 1595 1596 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 1633 1634 1605 1606 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 1651 1652 1619 1620 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1690 1691 1658 1659 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 1728 1729 1696 1697 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 1738 1739 1706 1707 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 1751 1752 1719 1720 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
###xml 1762 1763 1730 1731 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</bold>
###xml 1819 1820 1787 1788 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</bold>
###xml 1917 1921 1881 1885 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 1987 1988 1951 1952 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I</bold>
###xml 1056 2133 1036 2095 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="54"> Silencing PrP<sup>c</sup> in antigen specific splenocytes increases the expression of Th1 cytokines by upregulating T box expressed in T cells (T-bet). Splenocytes from SJL/J mice immunized with PLP<sub>p139&#8211;151</sub> and treated concomitantly intravenously with 50 &#181;g of <italic>Prnp</italic>-siRNA or nonsense (NS)-siRNA, were brought into single cell suspension 3 days after immunization and were pulsed with PLP<sub>p139&#8211;151</sub>. Interleukin (IL)-2, interferon (IFN)-&#947;, IL-17, IL-4, IL-5 and IL-10 cytokine expression was measured by ELISA. Silencing of PrP<sup>c</sup> significantly increased the expression of (<bold>A</bold>) IL-2, (<bold>B</bold>) IFN-&#947; and (<bold>C</bold>) IL-17. In contrast, silencing of PrP<sup>c</sup> had no effect on the expression of (<bold>D</bold>) IL-4, (<bold>E</bold>) IL-5 and (<bold>F</bold>) IL-10. (<bold>G</bold>) Protein expression of T box expressed in T cells and (<bold>H</bold>) retinoic acid receptor related orphan receptor (ROR)&#947;t in splenocytes of mice treated with <italic>Prnp</italic>-siRNA was increased compared with nonsense-siRNA-treated cells. (<bold>I</bold>) In contrast, the expression of GATA binding protein (GATA)-3 was not altered. The data are shown as mean clinical score &#177; standard deviation.</p>
###xml 1056 2133 1036 2095 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="54"> Silencing PrP<sup>c</sup> in antigen specific splenocytes increases the expression of Th1 cytokines by upregulating T box expressed in T cells (T-bet). Splenocytes from SJL/J mice immunized with PLP<sub>p139&#8211;151</sub> and treated concomitantly intravenously with 50 &#181;g of <italic>Prnp</italic>-siRNA or nonsense (NS)-siRNA, were brought into single cell suspension 3 days after immunization and were pulsed with PLP<sub>p139&#8211;151</sub>. Interleukin (IL)-2, interferon (IFN)-&#947;, IL-17, IL-4, IL-5 and IL-10 cytokine expression was measured by ELISA. Silencing of PrP<sup>c</sup> significantly increased the expression of (<bold>A</bold>) IL-2, (<bold>B</bold>) IFN-&#947; and (<bold>C</bold>) IL-17. In contrast, silencing of PrP<sup>c</sup> had no effect on the expression of (<bold>D</bold>) IL-4, (<bold>E</bold>) IL-5 and (<bold>F</bold>) IL-10. (<bold>G</bold>) Protein expression of T box expressed in T cells and (<bold>H</bold>) retinoic acid receptor related orphan receptor (ROR)&#947;t in splenocytes of mice treated with <italic>Prnp</italic>-siRNA was increased compared with nonsense-siRNA-treated cells. (<bold>I</bold>) In contrast, the expression of GATA binding protein (GATA)-3 was not altered. The data are shown as mean clinical score &#177; standard deviation.</p></caption>
###xml 2133 2133 2095 2095 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="awp298f3"/>
###xml 1048 2133 1028 2095 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F3" position="float"><label>Figure 3</label><caption><p textid="54"> Silencing PrP<sup>c</sup> in antigen specific splenocytes increases the expression of Th1 cytokines by upregulating T box expressed in T cells (T-bet). Splenocytes from SJL/J mice immunized with PLP<sub>p139&#8211;151</sub> and treated concomitantly intravenously with 50 &#181;g of <italic>Prnp</italic>-siRNA or nonsense (NS)-siRNA, were brought into single cell suspension 3 days after immunization and were pulsed with PLP<sub>p139&#8211;151</sub>. Interleukin (IL)-2, interferon (IFN)-&#947;, IL-17, IL-4, IL-5 and IL-10 cytokine expression was measured by ELISA. Silencing of PrP<sup>c</sup> significantly increased the expression of (<bold>A</bold>) IL-2, (<bold>B</bold>) IFN-&#947; and (<bold>C</bold>) IL-17. In contrast, silencing of PrP<sup>c</sup> had no effect on the expression of (<bold>D</bold>) IL-4, (<bold>E</bold>) IL-5 and (<bold>F</bold>) IL-10. (<bold>G</bold>) Protein expression of T box expressed in T cells and (<bold>H</bold>) retinoic acid receptor related orphan receptor (ROR)&#947;t in splenocytes of mice treated with <italic>Prnp</italic>-siRNA was increased compared with nonsense-siRNA-treated cells. (<bold>I</bold>) In contrast, the expression of GATA binding protein (GATA)-3 was not altered. The data are shown as mean clinical score &#177; standard deviation.</p></caption><graphic xlink:href="awp298f3"/></fig>
###xml 23 27 <span type="species:ncbi:10090">mice</span>
###xml 353 357 <span type="species:ncbi:10090">mice</span>
###xml 855 859 <span type="species:ncbi:10090">mice</span>
###xml 1221 1225 <span type="species:ncbi:10090">mice</span>
###xml 1899 1903 <span type="species:ncbi:10090">mice</span>
Splenocytes from SJL/J mice immunized with PLPp139-151 and treated intravenously with 50 microg of Prnp-siRNA or nonsense-siRNA were brought into single cell suspension 3 days after immunization and were pulsed with PLPp139-151. IL-2, IFNgamma, IL-17, IL-4, IL-5 and IL-10 cytokine expression in culture supernatants was measured by ELISA. Treatment of mice with Prnp-siRNA significantly increased the expression of IL-2 (Fig. 3A), interferon-gamma (Fig. 3B) and IL-17 (Fig. 3C). In contrast, there was no effect of silencing PrPc with siRNA on the expression of IL-4 (Fig. 3D), IL-5 (Fig. 3E) and IL-10 (Fig. 3F). Protein expression of T box expressed in T cells, a transcription factor that regulates IFNgamma and IL-17 expression, and (H) retinoic acid receptor-related orphan receptor (ROR)gammat, a regulator of IL-17 was increased in splenocytes of mice treated with Prnp-siRNA compared with nonsense-siRNA-treated cells (Fig. 3G and H). The expression of the Th2 transcription factor GATA binding protein (GATA)-3 was not altered (Fig. 3I). Figure 3 Silencing PrPc in antigen specific splenocytes increases the expression of Th1 cytokines by upregulating T box expressed in T cells (T-bet). Splenocytes from SJL/J mice immunized with PLPp139-151 and treated concomitantly intravenously with 50 microg of Prnp-siRNA or nonsense (NS)-siRNA, were brought into single cell suspension 3 days after immunization and were pulsed with PLPp139-151. Interleukin (IL)-2, interferon (IFN)-gamma, IL-17, IL-4, IL-5 and IL-10 cytokine expression was measured by ELISA. Silencing of PrPc significantly increased the expression of (A) IL-2, (B) IFN-gamma and (C) IL-17. In contrast, silencing of PrPc had no effect on the expression of (D) IL-4, (E) IL-5 and (F) IL-10. (G) Protein expression of T box expressed in T cells and (H) retinoic acid receptor related orphan receptor (ROR)gammat in splenocytes of mice treated with Prnp-siRNA was increased compared with nonsense-siRNA-treated cells. (I) In contrast, the expression of GATA binding protein (GATA)-3 was not altered. The data are shown as mean clinical score +/- standard deviation.
###end p 53
###begin p 54
###xml 14 15 14 15 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 188 196 188 196 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p139&#8211;151</sub>
###xml 255 259 251 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 381 389 377 385 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p139&#8211;151</sub>
###xml 522 523 514 515 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 567 568 559 560 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 577 578 569 570 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 595 596 583 584 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 634 635 622 623 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 672 673 660 661 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 682 683 670 671 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 695 696 683 684 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
###xml 706 707 694 695 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</bold>
###xml 763 764 751 752 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</bold>
###xml 861 865 845 849 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 931 932 915 916 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I</bold>
###xml 165 169 <span type="species:ncbi:10090">mice</span>
###xml 843 847 <span type="species:ncbi:10090">mice</span>
 Silencing PrPc in antigen specific splenocytes increases the expression of Th1 cytokines by upregulating T box expressed in T cells (T-bet). Splenocytes from SJL/J mice immunized with PLPp139-151 and treated concomitantly intravenously with 50 microg of Prnp-siRNA or nonsense (NS)-siRNA, were brought into single cell suspension 3 days after immunization and were pulsed with PLPp139-151. Interleukin (IL)-2, interferon (IFN)-gamma, IL-17, IL-4, IL-5 and IL-10 cytokine expression was measured by ELISA. Silencing of PrPc significantly increased the expression of (A) IL-2, (B) IFN-gamma and (C) IL-17. In contrast, silencing of PrPc had no effect on the expression of (D) IL-4, (E) IL-5 and (F) IL-10. (G) Protein expression of T box expressed in T cells and (H) retinoic acid receptor related orphan receptor (ROR)gammat in splenocytes of mice treated with Prnp-siRNA was increased compared with nonsense-siRNA-treated cells. (I) In contrast, the expression of GATA binding protein (GATA)-3 was not altered. The data are shown as mean clinical score +/- standard deviation.
###end p 54
###begin title 55
###xml 16 17 16 17 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
Silencing of PrPc augments antigen-specific T cell proliferation and activation
###end title 55
###begin p 56
###xml 17 23 17 23 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Fig. 4</xref>
###xml 43 49 43 49 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Fig. 4</xref>
###xml 57 61 57 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 251 252 251 252 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 312 316 312 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 352 358 352 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Fig. 4</xref>
###xml 377 378 377 378 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 659 663 659 663 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 742 748 742 748 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Fig. 4</xref>
###xml 758 764 758 764 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 766 770 766 770 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">1989</xref>
###xml 876 884 876 884 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4</label>
###xml 898 899 898 899 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 984 985 984 985 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 1015 1016 1015 1016 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 1064 1072 1064 1072 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p139&#8211;151</sub>
###xml 1090 1094 1090 1094 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 1227 1228 1227 1228 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 1252 1253 1252 1253 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 1272 1276 1272 1276 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 1329 1330 1329 1330 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1332 1336 1332 1336 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 1536 1537 1536 1537 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 1570 1574 1570 1574 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 884 1707 884 1707 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="57"> Silencing PrP<sup>c</sup> in antigen-specific T cells increases T cell proliferation and activation markers. (<bold>A</bold>) Lymph node cells (LNC) and (<bold>B</bold>) splenocytes from SJL/J mice immunized with PLP<sub>p139&#8211;151</sub> and treated with <italic>Prnp</italic>-siRNA or nonsense (NS)-RNA at the time of immunization were brought into single cell suspension on day 10 after immunization. Both (<bold>A</bold>) Lymph node cells and (<bold>B</bold>) splenocytes from <italic>Prnp</italic>-siRNA-treated mice showed increased proliferation. (<bold>C</bold>) <italic>Prnp</italic>-siRNA treatment also significantly increased the mean fluorescence intensity (MFI) of the activation marker CD25 in D10 T cells activated by anti-CD3, with or without anti-CD28 monoclonal antibody. (<bold>D</bold>) There was less of an effect of <italic>Prnp</italic>-siRNA treatment on the expression of CD69, an early T cell activation marker. Proliferation was measured as counts per minute (CPM).</p>
###xml 884 1707 884 1707 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="57"> Silencing PrP<sup>c</sup> in antigen-specific T cells increases T cell proliferation and activation markers. (<bold>A</bold>) Lymph node cells (LNC) and (<bold>B</bold>) splenocytes from SJL/J mice immunized with PLP<sub>p139&#8211;151</sub> and treated with <italic>Prnp</italic>-siRNA or nonsense (NS)-RNA at the time of immunization were brought into single cell suspension on day 10 after immunization. Both (<bold>A</bold>) Lymph node cells and (<bold>B</bold>) splenocytes from <italic>Prnp</italic>-siRNA-treated mice showed increased proliferation. (<bold>C</bold>) <italic>Prnp</italic>-siRNA treatment also significantly increased the mean fluorescence intensity (MFI) of the activation marker CD25 in D10 T cells activated by anti-CD3, with or without anti-CD28 monoclonal antibody. (<bold>D</bold>) There was less of an effect of <italic>Prnp</italic>-siRNA treatment on the expression of CD69, an early T cell activation marker. Proliferation was measured as counts per minute (CPM).</p></caption>
###xml 1707 1707 1707 1707 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="awp298f4"/>
###xml 876 1707 876 1707 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F4" position="float"><label>Figure 4</label><caption><p textid="57"> Silencing PrP<sup>c</sup> in antigen-specific T cells increases T cell proliferation and activation markers. (<bold>A</bold>) Lymph node cells (LNC) and (<bold>B</bold>) splenocytes from SJL/J mice immunized with PLP<sub>p139&#8211;151</sub> and treated with <italic>Prnp</italic>-siRNA or nonsense (NS)-RNA at the time of immunization were brought into single cell suspension on day 10 after immunization. Both (<bold>A</bold>) Lymph node cells and (<bold>B</bold>) splenocytes from <italic>Prnp</italic>-siRNA-treated mice showed increased proliferation. (<bold>C</bold>) <italic>Prnp</italic>-siRNA treatment also significantly increased the mean fluorescence intensity (MFI) of the activation marker CD25 in D10 T cells activated by anti-CD3, with or without anti-CD28 monoclonal antibody. (<bold>D</bold>) There was less of an effect of <italic>Prnp</italic>-siRNA treatment on the expression of CD69, an early T cell activation marker. Proliferation was measured as counts per minute (CPM).</p></caption><graphic xlink:href="awp298f4"/></fig>
###xml 76 80 <span type="species:ncbi:10090">mice</span>
###xml 199 203 <span type="species:ncbi:10090">mice</span>
###xml 1041 1045 <span type="species:ncbi:10090">mice</span>
###xml 1291 1295 <span type="species:ncbi:10090">mice</span>
Lmph node cells (Fig. 4A) and splenocytes (Fig. 4B) from Prnp-siRNA-treated mice showed significantly increased antigen-specific proliferation compared with cells from nonsense-siRNA-treated control mice. In an effort to understand the function of PrPc in T cells further, we tested the activation status of the Prnp-siRNA-treated T cells. As shown in Fig. 4C, silencing of PrPc augmented the expression of the activation marker CD25 in T cells stimulated with anti-CD3, with or without addition of anti-CD28 monoclonal antibody. The effect on CD25 appeared to be most pronounced in the presence of both anti-CD3 and anti-CD28. There was less of an effect of Prnp-siRNA treatment on the expression of CD69, an early T cell activation marker (Fig. 4D) (Testi et al., 1989), although some increase in CD69 expression was observed in conjunction with anti-CD3 stimulation alone. Figure 4 Silencing PrPc in antigen-specific T cells increases T cell proliferation and activation markers. (A) Lymph node cells (LNC) and (B) splenocytes from SJL/J mice immunized with PLPp139-151 and treated with Prnp-siRNA or nonsense (NS)-RNA at the time of immunization were brought into single cell suspension on day 10 after immunization. Both (A) Lymph node cells and (B) splenocytes from Prnp-siRNA-treated mice showed increased proliferation. (C) Prnp-siRNA treatment also significantly increased the mean fluorescence intensity (MFI) of the activation marker CD25 in D10 T cells activated by anti-CD3, with or without anti-CD28 monoclonal antibody. (D) There was less of an effect of Prnp-siRNA treatment on the expression of CD69, an early T cell activation marker. Proliferation was measured as counts per minute (CPM).
###end p 56
###begin p 57
###xml 14 15 14 15 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 100 101 100 101 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 131 132 131 132 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 180 188 180 188 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p139&#8211;151</sub>
###xml 206 210 206 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 343 344 343 344 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 368 369 368 369 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 388 392 388 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 445 446 445 446 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 448 452 448 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 652 653 652 653 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 686 690 686 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 157 161 <span type="species:ncbi:10090">mice</span>
###xml 407 411 <span type="species:ncbi:10090">mice</span>
 Silencing PrPc in antigen-specific T cells increases T cell proliferation and activation markers. (A) Lymph node cells (LNC) and (B) splenocytes from SJL/J mice immunized with PLPp139-151 and treated with Prnp-siRNA or nonsense (NS)-RNA at the time of immunization were brought into single cell suspension on day 10 after immunization. Both (A) Lymph node cells and (B) splenocytes from Prnp-siRNA-treated mice showed increased proliferation. (C) Prnp-siRNA treatment also significantly increased the mean fluorescence intensity (MFI) of the activation marker CD25 in D10 T cells activated by anti-CD3, with or without anti-CD28 monoclonal antibody. (D) There was less of an effect of Prnp-siRNA treatment on the expression of CD69, an early T cell activation marker. Proliferation was measured as counts per minute (CPM).
###end p 57
###begin title 58
###xml 81 82 81 82 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
T cells, not antigen presenting cells, mediate the proinflammatory effects of PrPC silencing
###end title 58
###begin p 59
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 53 59 53 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 61 65 61 65 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">1990</xref>
###xml 73 79 73 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 81 85 81 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">2000</xref>
###xml 90 96 90 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 98 102 98 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">2001</xref>
###xml 244 245 244 245 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 509 510 509 510 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 523 527 523 527 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;11</sub>
###xml 561 567 561 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 569 573 569 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">1993</xref>
###xml 637 641 637 641 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 649 655 649 655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Fig. 5</xref>
###xml 681 682 681 682 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 715 721 715 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Fig. 5</xref>
###xml 749 750 749 750 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 774 780 774 780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Fig. 5</xref>
###xml 924 925 920 921 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 1006 1012 1002 1008 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Fig. 5</xref>
###xml 1047 1048 1043 1044 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 1142 1148 1138 1144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Fig. 5</xref>
###xml 1154 1162 1150 1158 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5</label>
###xml 1211 1215 1207 1211 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 1224 1225 1220 1221 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 1319 1323 1315 1319 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;11</sub>
###xml 1342 1343 1338 1339 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1370 1374 1366 1370 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 1448 1449 1444 1445 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 1521 1522 1517 1518 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 1612 1613 1608 1609 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 1633 1634 1629 1630 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 1717 1718 1713 1714 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 1742 1743 1738 1739 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1752 1753 1748 1749 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 1835 1836 1831 1832 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 1856 1860 1852 1856 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 1884 1888 1880 1884 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 1959 1963 1955 1959 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 2040 2041 2036 2037 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
###xml 2046 2047 2042 2043 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 2065 2069 2061 2065 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 1162 2111 1158 2107 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="60"> Antigen-specific T cells are the main target of <italic>Prnp</italic>-siRNA. (<bold>A</bold>) Irradiated splenocytes from B10PL mice that served as antigen presenting cells (APC), or MBP<sub>1&#8211;11</sub> TCR transgenic CD4<sup>+</sup> T cells were treated with <italic>Prnp</italic>-siRNA and/or nonsense-siRNA, and incubated with antigen. Silencing of PrP<sup>c</sup> in T cells results in increased proliferation, whereas silencing of PrP<sup>c</sup> in antigen presenting cells had no apparent effect on T cell proliferation. Targeting PrP<sup>c</sup> in T cells with a (<bold>B</bold>) single chain variable fragment (scFv), or two monoclonal mouse anti-mouse PrP IgG<sub>1</sub> monoclonal antibodies (<bold>C</bold>) 19C4, (<bold>D</bold>) W226 also resulted in the augmented proliferation of antigen-specific T cells. (<bold>E</bold>) Mice treated with <italic>Prnp</italic>-siRNA as recipients of <italic>Prnp</italic>-siRNA-treated adoptively transferred T cells, as recipients of direct <italic>Prnp</italic>-siRNA treatment, or both, developed significantly worse EAE than controls. (<bold>F</bold>) PrP<sup>c</sup> expression after <italic>Prnp</italic>-siRNA treatment is suppressed for 5 days.</p>
###xml 1162 2111 1158 2107 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="60"> Antigen-specific T cells are the main target of <italic>Prnp</italic>-siRNA. (<bold>A</bold>) Irradiated splenocytes from B10PL mice that served as antigen presenting cells (APC), or MBP<sub>1&#8211;11</sub> TCR transgenic CD4<sup>+</sup> T cells were treated with <italic>Prnp</italic>-siRNA and/or nonsense-siRNA, and incubated with antigen. Silencing of PrP<sup>c</sup> in T cells results in increased proliferation, whereas silencing of PrP<sup>c</sup> in antigen presenting cells had no apparent effect on T cell proliferation. Targeting PrP<sup>c</sup> in T cells with a (<bold>B</bold>) single chain variable fragment (scFv), or two monoclonal mouse anti-mouse PrP IgG<sub>1</sub> monoclonal antibodies (<bold>C</bold>) 19C4, (<bold>D</bold>) W226 also resulted in the augmented proliferation of antigen-specific T cells. (<bold>E</bold>) Mice treated with <italic>Prnp</italic>-siRNA as recipients of <italic>Prnp</italic>-siRNA-treated adoptively transferred T cells, as recipients of direct <italic>Prnp</italic>-siRNA treatment, or both, developed significantly worse EAE than controls. (<bold>F</bold>) PrP<sup>c</sup> expression after <italic>Prnp</italic>-siRNA treatment is suppressed for 5 days.</p></caption>
###xml 2111 2111 2107 2107 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="awp298f5"/>
###xml 1154 2111 1150 2107 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F5" position="float"><label>Figure 5</label><caption><p textid="60"> Antigen-specific T cells are the main target of <italic>Prnp</italic>-siRNA. (<bold>A</bold>) Irradiated splenocytes from B10PL mice that served as antigen presenting cells (APC), or MBP<sub>1&#8211;11</sub> TCR transgenic CD4<sup>+</sup> T cells were treated with <italic>Prnp</italic>-siRNA and/or nonsense-siRNA, and incubated with antigen. Silencing of PrP<sup>c</sup> in T cells results in increased proliferation, whereas silencing of PrP<sup>c</sup> in antigen presenting cells had no apparent effect on T cell proliferation. Targeting PrP<sup>c</sup> in T cells with a (<bold>B</bold>) single chain variable fragment (scFv), or two monoclonal mouse anti-mouse PrP IgG<sub>1</sub> monoclonal antibodies (<bold>C</bold>) 19C4, (<bold>D</bold>) W226 also resulted in the augmented proliferation of antigen-specific T cells. (<bold>E</bold>) Mice treated with <italic>Prnp</italic>-siRNA as recipients of <italic>Prnp</italic>-siRNA-treated adoptively transferred T cells, as recipients of direct <italic>Prnp</italic>-siRNA treatment, or both, developed significantly worse EAE than controls. (<bold>F</bold>) PrP<sup>c</sup> expression after <italic>Prnp</italic>-siRNA treatment is suppressed for 5 days.</p></caption><graphic xlink:href="awp298f5"/></fig>
###xml 427 431 <span type="species:ncbi:10090">mice</span>
###xml 1261 1265 <span type="species:ncbi:10090">mice</span>
###xml 1693 1698 <span type="species:ncbi:10090">mouse</span>
###xml 1704 1709 <span type="species:ncbi:10090">mouse</span>
###xml 1838 1842 <span type="species:ncbi:10090">Mice</span>
PrPc is constitutively expressed in T cells (Cashman et al., 1990; Durig et al., 2000; Li et al., 2001) and cells that can serve as antigen-presenting cells, including B cells and dendritic cells. Thus, we investigated whether the effect of PrPc on T cell proliferation was predominantly mediated through its effects on T cells, or antigen-presenting cells or both. Specifically, sublethally irradiated splenocytes from B10.PL mice were used as antigen-presenting cells and presented MBP peptide Ac1-11 to CD4+-enriched MBP1-11 TCR transgenic T cells (Goverman et al., 1993). Either antigen-presenting cells or T cells were treated with Prnp-siRNA (Fig. 5A), a recombinant anti-PrPc single chain variable fragment (Fig. 5B), or two distinct anti-PrPc monoclonal antibodies (Fig. 5C and D) at a dose of 1 microg/ml for 24 h prior to the proliferation assay (for details, see Experimental Procedures section). Silencing of PrPc in antigen-specific T cells resulted in increased proliferation of these cells (Fig. 5A-D). In contrast, silencing of PrPc in antigen-presenting cells had no apparent effect on antigen-specific T cell proliferation (Fig. 5A-D). Figure 5 Antigen-specific T cells are the main target of Prnp-siRNA. (A) Irradiated splenocytes from B10PL mice that served as antigen presenting cells (APC), or MBP1-11 TCR transgenic CD4+ T cells were treated with Prnp-siRNA and/or nonsense-siRNA, and incubated with antigen. Silencing of PrPc in T cells results in increased proliferation, whereas silencing of PrPc in antigen presenting cells had no apparent effect on T cell proliferation. Targeting PrPc in T cells with a (B) single chain variable fragment (scFv), or two monoclonal mouse anti-mouse PrP IgG1 monoclonal antibodies (C) 19C4, (D) W226 also resulted in the augmented proliferation of antigen-specific T cells. (E) Mice treated with Prnp-siRNA as recipients of Prnp-siRNA-treated adoptively transferred T cells, as recipients of direct Prnp-siRNA treatment, or both, developed significantly worse EAE than controls. (F) PrPc expression after Prnp-siRNA treatment is suppressed for 5 days.
###end p 59
###begin p 60
###xml 49 53 49 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 62 63 62 63 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 157 161 157 161 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;11</sub>
###xml 180 181 180 181 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 208 212 208 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 286 287 286 287 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 359 360 359 360 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 450 451 450 451 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 471 472 471 472 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 555 556 555 556 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 580 581 580 581 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 590 591 590 591 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 673 674 673 674 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 694 698 694 698 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 722 726 722 726 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 797 801 797 801 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 878 879 878 879 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
###xml 884 885 884 885 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 903 907 903 907 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 99 103 <span type="species:ncbi:10090">mice</span>
###xml 531 536 <span type="species:ncbi:10090">mouse</span>
###xml 542 547 <span type="species:ncbi:10090">mouse</span>
###xml 676 680 <span type="species:ncbi:10090">Mice</span>
 Antigen-specific T cells are the main target of Prnp-siRNA. (A) Irradiated splenocytes from B10PL mice that served as antigen presenting cells (APC), or MBP1-11 TCR transgenic CD4+ T cells were treated with Prnp-siRNA and/or nonsense-siRNA, and incubated with antigen. Silencing of PrPc in T cells results in increased proliferation, whereas silencing of PrPc in antigen presenting cells had no apparent effect on T cell proliferation. Targeting PrPc in T cells with a (B) single chain variable fragment (scFv), or two monoclonal mouse anti-mouse PrP IgG1 monoclonal antibodies (C) 19C4, (D) W226 also resulted in the augmented proliferation of antigen-specific T cells. (E) Mice treated with Prnp-siRNA as recipients of Prnp-siRNA-treated adoptively transferred T cells, as recipients of direct Prnp-siRNA treatment, or both, developed significantly worse EAE than controls. (F) PrPc expression after Prnp-siRNA treatment is suppressed for 5 days.
###end p 60
###begin p 61
###xml 12 19 12 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 115 123 115 123 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p139&#8211;151</sub>
###xml 164 168 164 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 261 265 261 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 377 381 377 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 458 462 458 462 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 483 487 483 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 581 585 581 585 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 613 619 613 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Fig. 5</xref>
###xml 629 630 629 630 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 740 746 740 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Fig. 5</xref>
###xml 236 240 <span type="species:ncbi:10090">mice</span>
###xml 359 363 <span type="species:ncbi:10090">mice</span>
###xml 440 444 <span type="species:ncbi:10090">mice</span>
###xml 534 538 <span type="species:ncbi:10090">mice</span>
To test the in vivo relevance of this observation, reciprocal adoptive transfer EAE experiments were conducted. PLPp139-151-specific T cells that were treated with Prnp-siRNA or nonsense-siRNA were adoptively transferred into recipient mice treated with either Prnp-siRNA or nonsense-siRNA. Significant worsening of clinical EAE was observed in (i) recipient mice treated with Prnp-siRNA that received untreated donor cells; (ii) recipient mice treated with Prnp-siRNA that received Prnp-siRNA-treated donor cells and (iii) recipient mice treated with nonsense-siRNA that received Prnp-siRNA-treated donor cells (Fig. 5E, F). PrPc expression in draining lymph nodes was diminished in lymph node cells until Day 6 post siRNA administration (Fig. 5F).
###end p 61
###begin title 62
###xml 16 17 16 17 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
Silencing of PrPc in anti-CD3/CD28 activated T cells increases zeta-chain-associated protein-70 phosphorylation and nuclear factor of activated T cells/activator protein 1 reporter activity
###end title 62
###begin p 63
###xml 41 42 41 42 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 134 135 134 135 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 218 219 218 219 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 501 505 501 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 646 652 646 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Fig. 6</xref>
###xml 789 795 789 795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Fig. 6</xref>
###xml 799 807 799 807 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 6</label>
###xml 821 822 821 822 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 901 902 901 902 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 1002 1003 1002 1003 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1025 1029 1025 1029 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 1038 1039 1038 1039 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 1175 1179 1175 1179 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 1282 1283 1282 1283 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1351 1352 1351 1352 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">u</sup>
###xml 1415 1422 1415 1422 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1450 1454 1450 1454 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 1595 1599 1595 1599 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;11</sub>
###xml 807 1680 807 1680 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="64"> Silencing PrP<sup>c</sup> on T cells increases ZAP-70 phosphorylation and NFAT/AP-1 reporter activity. (<bold>A</bold>) Phosphorylation of ZAP-70 and the zeta chain of the TCR/CD3 complex was increased in activated CD4<sup>+</sup> T cells treated with <italic>Prnp</italic>-siRNA. (<bold>B</bold>) Transcription of an NFAT/AP-1 luciferase reporter was also significantly increased in activated and unstimulated T cells treated with <italic>Prnp</italic>-siRNA. In contrast, NFAT/AP-1 reporter activity was not altered in PMA/ionomycin-stimulated T cells. (<bold>C</bold>) MBP peptide AC1&#8211;11 TCR transgenic mice on a B10.PL background (I-A<sup>u</sup>) generated by Joan Goverman and coworkers developed EAE after <italic>in vivo</italic> intravenous treatment with <italic>Prnp</italic>-siRNA on Days 0, 3 and 6 of the observation period (indicated by grey arrows), but not after treatment with nonsense-siRNA. In contrast, MBP<sub>1&#8211;11</sub> TCR transgenic mice generated by Lafaille and coworkers did not develop disease.</p>
###xml 807 1680 807 1680 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="64"> Silencing PrP<sup>c</sup> on T cells increases ZAP-70 phosphorylation and NFAT/AP-1 reporter activity. (<bold>A</bold>) Phosphorylation of ZAP-70 and the zeta chain of the TCR/CD3 complex was increased in activated CD4<sup>+</sup> T cells treated with <italic>Prnp</italic>-siRNA. (<bold>B</bold>) Transcription of an NFAT/AP-1 luciferase reporter was also significantly increased in activated and unstimulated T cells treated with <italic>Prnp</italic>-siRNA. In contrast, NFAT/AP-1 reporter activity was not altered in PMA/ionomycin-stimulated T cells. (<bold>C</bold>) MBP peptide AC1&#8211;11 TCR transgenic mice on a B10.PL background (I-A<sup>u</sup>) generated by Joan Goverman and coworkers developed EAE after <italic>in vivo</italic> intravenous treatment with <italic>Prnp</italic>-siRNA on Days 0, 3 and 6 of the observation period (indicated by grey arrows), but not after treatment with nonsense-siRNA. In contrast, MBP<sub>1&#8211;11</sub> TCR transgenic mice generated by Lafaille and coworkers did not develop disease.</p></caption>
###xml 1680 1680 1680 1680 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="awp298f6"/>
###xml 799 1680 799 1680 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F6" position="float"><label>Figure 6</label><caption><p textid="64"> Silencing PrP<sup>c</sup> on T cells increases ZAP-70 phosphorylation and NFAT/AP-1 reporter activity. (<bold>A</bold>) Phosphorylation of ZAP-70 and the zeta chain of the TCR/CD3 complex was increased in activated CD4<sup>+</sup> T cells treated with <italic>Prnp</italic>-siRNA. (<bold>B</bold>) Transcription of an NFAT/AP-1 luciferase reporter was also significantly increased in activated and unstimulated T cells treated with <italic>Prnp</italic>-siRNA. In contrast, NFAT/AP-1 reporter activity was not altered in PMA/ionomycin-stimulated T cells. (<bold>C</bold>) MBP peptide AC1&#8211;11 TCR transgenic mice on a B10.PL background (I-A<sup>u</sup>) generated by Joan Goverman and coworkers developed EAE after <italic>in vivo</italic> intravenous treatment with <italic>Prnp</italic>-siRNA on Days 0, 3 and 6 of the observation period (indicated by grey arrows), but not after treatment with nonsense-siRNA. In contrast, MBP<sub>1&#8211;11</sub> TCR transgenic mice generated by Lafaille and coworkers did not develop disease.</p></caption><graphic xlink:href="awp298f6"/></fig>
###xml 1308 1323 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1604 1619 <span type="species:ncbi:10090">transgenic mice</span>
Our earlier results on the effects of PrPc on antigen-specific T cell activation, proliferation and differentiation suggested that PrPc may serve as an immunomodulatory molecule and specifically that the absence of PrPc amplified TCR signalling. Zeta-chain-associated protein (ZAP)-70, a member of the protein tyrosine kinase family, is constitutively expressed in T lymphocytes. The phosphorylation of ZAP-70 and its association with the zeta chain are upstream events in the TCR signalling pathway. Prnp-siRNA, but not nonsense-siRNA, treatment was associated with increased phosphorylation of ZAP-70 and the zeta chain of the TCR/CD3 complex (Fig. 6A). There was a less pronounced but detectable increase in tyrosine phosphorylation of the ZAP-70 substrate linker of activated T cells (Fig. 6A). Figure 6 Silencing PrPc on T cells increases ZAP-70 phosphorylation and NFAT/AP-1 reporter activity. (A) Phosphorylation of ZAP-70 and the zeta chain of the TCR/CD3 complex was increased in activated CD4+ T cells treated with Prnp-siRNA. (B) Transcription of an NFAT/AP-1 luciferase reporter was also significantly increased in activated and unstimulated T cells treated with Prnp-siRNA. In contrast, NFAT/AP-1 reporter activity was not altered in PMA/ionomycin-stimulated T cells. (C) MBP peptide AC1-11 TCR transgenic mice on a B10.PL background (I-Au) generated by Joan Goverman and coworkers developed EAE after in vivo intravenous treatment with Prnp-siRNA on Days 0, 3 and 6 of the observation period (indicated by grey arrows), but not after treatment with nonsense-siRNA. In contrast, MBP1-11 TCR transgenic mice generated by Lafaille and coworkers did not develop disease.
###end p 63
###begin p 64
###xml 14 15 14 15 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 94 95 94 95 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 195 196 195 196 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 218 222 218 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 231 232 231 232 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 368 372 368 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 475 476 475 476 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 544 545 544 545 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">u</sup>
###xml 608 615 608 615 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 643 647 643 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 788 792 788 792 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;11</sub>
###xml 501 516 <span type="species:ncbi:10090">transgenic mice</span>
###xml 797 812 <span type="species:ncbi:10090">transgenic mice</span>
 Silencing PrPc on T cells increases ZAP-70 phosphorylation and NFAT/AP-1 reporter activity. (A) Phosphorylation of ZAP-70 and the zeta chain of the TCR/CD3 complex was increased in activated CD4+ T cells treated with Prnp-siRNA. (B) Transcription of an NFAT/AP-1 luciferase reporter was also significantly increased in activated and unstimulated T cells treated with Prnp-siRNA. In contrast, NFAT/AP-1 reporter activity was not altered in PMA/ionomycin-stimulated T cells. (C) MBP peptide AC1-11 TCR transgenic mice on a B10.PL background (I-Au) generated by Joan Goverman and coworkers developed EAE after in vivo intravenous treatment with Prnp-siRNA on Days 0, 3 and 6 of the observation period (indicated by grey arrows), but not after treatment with nonsense-siRNA. In contrast, MBP1-11 TCR transgenic mice generated by Lafaille and coworkers did not develop disease.
###end p 64
###begin p 65
###xml 230 234 230 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 271 277 271 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Fig. 6</xref>
###xml 470 476 470 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Fig. 6</xref>
###xml 530 531 530 531 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
After activation with anti-CD3 and anti-CD28 monoclonal antibodies, transcription of an nuclear factor of activated T cells (NFAT)/activator protein 1 (AP-1) luciferase reporter was significantly increased in T cells treated with Prnp-siRNA compared with nonsense-siRNA (Fig. 6B). There was also a significant increase in unstimulated T cells. In contrast, NFAT/AP-1 reporter activity was not altered in phorbol 12-myristate 13-acetate and ionomycin stimulated T cells (Fig. 6B), consistent with the notion that the effects of PrPc silencing were primarily at the level of TCR-proximal signalling.
###end p 65
###begin title 66
###xml 13 14 13 14 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 83 87 83 87 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;11</sub>
###xml 104 119 <span type="species:ncbi:10090">transgenic mice</span>
Silencing PrPc induces spontaneous experimental autoimmune encephalomyelitis in MBP1-11 T cell receptor transgenic mice
###end title 66
###begin p 67
###xml 27 31 27 31 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;11</sub>
###xml 74 80 74 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 82 86 82 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">1993</xref>
###xml 101 107 101 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 109 113 109 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">1994</xref>
###xml 120 124 120 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 135 139 135 139 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;11</sub>
###xml 187 188 187 188 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">u</sup>
###xml 227 231 227 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">1993</xref>
###xml 359 365 359 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 367 371 367 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">1994</xref>
###xml 439 445 439 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 501 505 501 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 629 635 629 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Fig. 6</xref>
###xml 36 51 <span type="species:ncbi:10090">transgenic mice</span>
###xml 144 159 <span type="species:ncbi:10090">transgenic mice</span>
###xml 334 338 <span type="species:ncbi:10090">mice</span>
###xml 412 416 <span type="species:ncbi:10090">mice</span>
We treated two distinct MBP1-11 TCR transgenic mice generated by Goverman et al. (1993) and Lafaille et al. (1994) with Prnp-siRNA. MBP1-11 TCR transgenic mice on a B10.PL background (I-Au) generated by Goverman and coworkers (1993) were reported to have a higher incidence of spontaneous EAE in non-pathogen-free conditions than the mice created by Lafaille et al. (1994). Without the addition of antigen, only mice generated by Goverman et al. rapidly developed spontaneous EAE after treatment with Prnp-siRNA on Days 0, 3 and 6 of the observation period (indicated by red arrows), but not after treatment with nonsense-siRNA (Fig. 6C).
###end p 67
###begin title 68
###xml 13 14 13 14 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
Silencing PrPc promotes T cell survival
###end title 68
###begin p 69
###xml 39 40 39 40 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 158 162 158 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 211 218 211 218 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">323&#8211;339</sub>
###xml 245 246 245 246 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 250 251 250 251 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 310 311 310 311 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 355 362 355 362 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">323&#8211;339</sub>
###xml 476 480 476 480 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 505 506 505 506 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 516 523 516 523 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">323&#8211;339</sub>
###xml 542 543 542 543 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 620 626 620 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Fig. 7</xref>
###xml 693 700 693 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 743 750 743 750 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">323&#8211;339</sub>
###xml 769 770 769 770 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 796 800 796 800 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 808 814 808 814 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Fig. 7</xref>
###xml 842 848 842 848 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Fig. 7</xref>
###xml 978 985 978 985 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">323&#8211;339</sub>
###xml 1007 1008 1007 1008 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1012 1013 1012 1013 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1041 1047 1041 1047 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Fig. 7</xref>
###xml 1067 1073 1067 1073 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Fig. 7</xref>
###xml 1178 1185 1178 1185 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">323&#8211;339</sub>
###xml 1446 1454 1446 1454 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 7</label>
###xml 1471 1472 1471 1472 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 1499 1503 1499 1503 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 1552 1559 1552 1559 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">323&#8211;339</sub>
###xml 1581 1582 1581 1582 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1586 1587 1586 1587 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1646 1647 1646 1647 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1691 1698 1691 1698 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">323&#8211;339</sub>
###xml 1756 1757 1756 1757 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 1792 1796 1792 1796 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 1821 1822 1821 1822 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1832 1839 1832 1839 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">323&#8211;339</sub>
###xml 1858 1859 1858 1859 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2014 2021 2014 2021 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 2064 2071 2064 2071 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">323&#8211;339</sub>
###xml 2090 2091 2090 2091 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2118 2119 2118 2119 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 2121 2125 2121 2125 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 2142 2143 2142 2143 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 2167 2168 2167 2168 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 2187 2188 2187 2188 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 2304 2311 2304 2311 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">323&#8211;339</sub>
###xml 2394 2395 2394 2395 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
###xml 2441 2442 2441 2442 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2446 2450 2446 2450 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;11</sub>
###xml 2525 2533 2525 2533 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 2639 2640 2639 2640 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2644 2648 2644 2648 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;11</sub>
###xml 2685 2689 2685 2689 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 2698 2699 2698 2699 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</bold>
###xml 2750 2751 2750 2751 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 1454 2780 1454 2780 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="70"> Silencing of PrP<sup>c</sup> improves T cell survival. <italic>Prnp</italic>-siRNA or nonsense-siRNA-transfected purified OVA<sub>323&#8211;339</sub> TCR transgenic CD45.2<sup>+</sup> CD4<sup>+</sup> T cells were transferred intravenously into C57BL/6 CD45.1<sup>+</sup> wild-type mice that were immunized with OVA<sub>323&#8211;339</sub> in complete freund's adjuvant 24 h after cell transfer. (<bold>A</bold>) A significantly higher number of <italic>Prnp</italic>-siRNA-transfected CD45.2<sup>+</sup> donor OVA<sub>323&#8211;339</sub> TCR transgenic CD4<sup>+</sup> T cells were recovered from lymph nodes and spleens than nonsense-siRNA-transfected cells. At Day 5 post transfer, there was no difference with regard to <italic>in vivo</italic> antigen-specific proliferation between OVA<sub>323&#8211;339</sub> TCR transgenic CD4<sup>+</sup> T cells transfected with (<bold>B</bold>) <italic>Prnp</italic>-siRNA, or with (<bold>C</bold>) nonsense-siRNA. When (<bold>D</bold>) lymph nodes and (<bold>E</bold>) splenocytes of recipient mice were resected on Day 3 after immunization, and recall assays were performed with OVA<sub>323&#8211;339</sub>, a significant increase in cell proliferation in both compartments was observed. (<bold>F</bold>) The number of purified antigen-activated CD4<sup>+</sup> MBP<sub>1&#8211;11</sub> TCR transgenic T cells transfected with nonsense-siRNA started to decline <italic>in vitro</italic> on Day 3, and none of the cells were viable on Day 10. Cell numbers remained relatively stable in the CD4<sup>+</sup> MBP<sub>1&#8211;11</sub> TCR transgenic T cells treated with <italic>Prnp</italic>-siRNA. (<bold>G</bold>) Schematic of proposed mechanisms of action of PrP<sup>c</sup> in antigen-specific T cells.</p>
###xml 1454 2780 1454 2780 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="70"> Silencing of PrP<sup>c</sup> improves T cell survival. <italic>Prnp</italic>-siRNA or nonsense-siRNA-transfected purified OVA<sub>323&#8211;339</sub> TCR transgenic CD45.2<sup>+</sup> CD4<sup>+</sup> T cells were transferred intravenously into C57BL/6 CD45.1<sup>+</sup> wild-type mice that were immunized with OVA<sub>323&#8211;339</sub> in complete freund's adjuvant 24 h after cell transfer. (<bold>A</bold>) A significantly higher number of <italic>Prnp</italic>-siRNA-transfected CD45.2<sup>+</sup> donor OVA<sub>323&#8211;339</sub> TCR transgenic CD4<sup>+</sup> T cells were recovered from lymph nodes and spleens than nonsense-siRNA-transfected cells. At Day 5 post transfer, there was no difference with regard to <italic>in vivo</italic> antigen-specific proliferation between OVA<sub>323&#8211;339</sub> TCR transgenic CD4<sup>+</sup> T cells transfected with (<bold>B</bold>) <italic>Prnp</italic>-siRNA, or with (<bold>C</bold>) nonsense-siRNA. When (<bold>D</bold>) lymph nodes and (<bold>E</bold>) splenocytes of recipient mice were resected on Day 3 after immunization, and recall assays were performed with OVA<sub>323&#8211;339</sub>, a significant increase in cell proliferation in both compartments was observed. (<bold>F</bold>) The number of purified antigen-activated CD4<sup>+</sup> MBP<sub>1&#8211;11</sub> TCR transgenic T cells transfected with nonsense-siRNA started to decline <italic>in vitro</italic> on Day 3, and none of the cells were viable on Day 10. Cell numbers remained relatively stable in the CD4<sup>+</sup> MBP<sub>1&#8211;11</sub> TCR transgenic T cells treated with <italic>Prnp</italic>-siRNA. (<bold>G</bold>) Schematic of proposed mechanisms of action of PrP<sup>c</sup> in antigen-specific T cells.</p></caption>
###xml 2780 2780 2780 2780 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="awp298f7"/>
###xml 1446 2780 1446 2780 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F7" position="float"><label>Figure 7</label><caption><p textid="70"> Silencing of PrP<sup>c</sup> improves T cell survival. <italic>Prnp</italic>-siRNA or nonsense-siRNA-transfected purified OVA<sub>323&#8211;339</sub> TCR transgenic CD45.2<sup>+</sup> CD4<sup>+</sup> T cells were transferred intravenously into C57BL/6 CD45.1<sup>+</sup> wild-type mice that were immunized with OVA<sub>323&#8211;339</sub> in complete freund's adjuvant 24 h after cell transfer. (<bold>A</bold>) A significantly higher number of <italic>Prnp</italic>-siRNA-transfected CD45.2<sup>+</sup> donor OVA<sub>323&#8211;339</sub> TCR transgenic CD4<sup>+</sup> T cells were recovered from lymph nodes and spleens than nonsense-siRNA-transfected cells. At Day 5 post transfer, there was no difference with regard to <italic>in vivo</italic> antigen-specific proliferation between OVA<sub>323&#8211;339</sub> TCR transgenic CD4<sup>+</sup> T cells transfected with (<bold>B</bold>) <italic>Prnp</italic>-siRNA, or with (<bold>C</bold>) nonsense-siRNA. When (<bold>D</bold>) lymph nodes and (<bold>E</bold>) splenocytes of recipient mice were resected on Day 3 after immunization, and recall assays were performed with OVA<sub>323&#8211;339</sub>, a significant increase in cell proliferation in both compartments was observed. (<bold>F</bold>) The number of purified antigen-activated CD4<sup>+</sup> MBP<sub>1&#8211;11</sub> TCR transgenic T cells transfected with nonsense-siRNA started to decline <italic>in vitro</italic> on Day 3, and none of the cells were viable on Day 10. Cell numbers remained relatively stable in the CD4<sup>+</sup> MBP<sub>1&#8211;11</sub> TCR transgenic T cells treated with <italic>Prnp</italic>-siRNA. (<bold>G</bold>) Schematic of proposed mechanisms of action of PrP<sup>c</sup> in antigen-specific T cells.</p></caption><graphic xlink:href="awp298f7"/></fig>
###xml 223 238 <span type="species:ncbi:10090">transgenic mice</span>
###xml 322 326 <span type="species:ncbi:10090">mice</span>
###xml 1089 1093 <span type="species:ncbi:10090">mice</span>
###xml 1658 1662 <span type="species:ncbi:10090">mice</span>
###xml 2215 2219 <span type="species:ncbi:10090">mice</span>
To investigate whether an effect of PrPc on the survival of activated antigen-specific T cells may account for some of its effects on CNS autoimmune disease, Prnp-siRNA or nonsense-siRNA-transfected purified OVA323-339 TCR transgenic mice CD45.2+ CD4+ T cells were transferred intravenously into C57BL/6 CD45.1+ wild-type mice that were immunized with OVA323-339 in complete freund's adjuvant 24 h after cell transfer. We were able to recover a significantly higher number of Prnp-siRNA-transfected CD45.2+ donor OVA323-339 TCR transgenic CD4+ T cells from lymph nodes and spleens than nonsense-siRNA-transfected cells (Fig. 7A). At Day 5 post transfer, there was no difference with regard to in vivo antigen-specific proliferation between OVA323-339 TCR transgenic CD4+ T cells transfected with Prnp-siRNA (Fig. 7B), or with nonsense-siRNA (Fig. 7C) as shown by flow cytometric proliferation analysis of 5- (and 6-) carboxy fluorescein diacetate succinimidyl ester-labelled OVA323-339 TCR transgenic CD45.2+ CD4+ T cells. When lymph nodes (Fig. 7D) and splenocytes (Fig. 7E) of recipient mice were resected on Day 3 after immunization, and recall assays were performed with OVA323-339, we observed a significant increase in cell proliferation in both compartments. Thus, while there was no change in proliferative responses in antigen-specific T cells in both secondary lymphoid organs, there appeared to be bystander-activation of other cells. Figure 7 Silencing of PrPc improves T cell survival. Prnp-siRNA or nonsense-siRNA-transfected purified OVA323-339 TCR transgenic CD45.2+ CD4+ T cells were transferred intravenously into C57BL/6 CD45.1+ wild-type mice that were immunized with OVA323-339 in complete freund's adjuvant 24 h after cell transfer. (A) A significantly higher number of Prnp-siRNA-transfected CD45.2+ donor OVA323-339 TCR transgenic CD4+ T cells were recovered from lymph nodes and spleens than nonsense-siRNA-transfected cells. At Day 5 post transfer, there was no difference with regard to in vivo antigen-specific proliferation between OVA323-339 TCR transgenic CD4+ T cells transfected with (B) Prnp-siRNA, or with (C) nonsense-siRNA. When (D) lymph nodes and (E) splenocytes of recipient mice were resected on Day 3 after immunization, and recall assays were performed with OVA323-339, a significant increase in cell proliferation in both compartments was observed. (F) The number of purified antigen-activated CD4+ MBP1-11 TCR transgenic T cells transfected with nonsense-siRNA started to decline in vitro on Day 3, and none of the cells were viable on Day 10. Cell numbers remained relatively stable in the CD4+ MBP1-11 TCR transgenic T cells treated with Prnp-siRNA. (G) Schematic of proposed mechanisms of action of PrPc in antigen-specific T cells.
###end p 69
###begin p 70
###xml 17 18 17 18 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 45 49 45 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 98 105 98 105 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">323&#8211;339</sub>
###xml 127 128 127 128 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 132 133 132 133 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 192 193 192 193 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 237 244 237 244 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">323&#8211;339</sub>
###xml 302 303 302 303 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 338 342 338 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 367 368 367 368 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 378 385 378 385 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">323&#8211;339</sub>
###xml 404 405 404 405 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 560 567 560 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 610 617 610 617 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">323&#8211;339</sub>
###xml 636 637 636 637 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 664 665 664 665 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 667 671 667 671 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 688 689 688 689 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 713 714 713 714 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 733 734 733 734 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 850 857 850 857 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">323&#8211;339</sub>
###xml 940 941 940 941 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
###xml 987 988 987 988 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 992 996 992 996 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;11</sub>
###xml 1071 1079 1071 1079 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1185 1186 1185 1186 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1190 1194 1190 1194 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;11</sub>
###xml 1231 1235 1231 1235 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 1244 1245 1244 1245 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</bold>
###xml 1296 1297 1296 1297 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 204 208 <span type="species:ncbi:10090">mice</span>
###xml 761 765 <span type="species:ncbi:10090">mice</span>
 Silencing of PrPc improves T cell survival. Prnp-siRNA or nonsense-siRNA-transfected purified OVA323-339 TCR transgenic CD45.2+ CD4+ T cells were transferred intravenously into C57BL/6 CD45.1+ wild-type mice that were immunized with OVA323-339 in complete freund's adjuvant 24 h after cell transfer. (A) A significantly higher number of Prnp-siRNA-transfected CD45.2+ donor OVA323-339 TCR transgenic CD4+ T cells were recovered from lymph nodes and spleens than nonsense-siRNA-transfected cells. At Day 5 post transfer, there was no difference with regard to in vivo antigen-specific proliferation between OVA323-339 TCR transgenic CD4+ T cells transfected with (B) Prnp-siRNA, or with (C) nonsense-siRNA. When (D) lymph nodes and (E) splenocytes of recipient mice were resected on Day 3 after immunization, and recall assays were performed with OVA323-339, a significant increase in cell proliferation in both compartments was observed. (F) The number of purified antigen-activated CD4+ MBP1-11 TCR transgenic T cells transfected with nonsense-siRNA started to decline in vitro on Day 3, and none of the cells were viable on Day 10. Cell numbers remained relatively stable in the CD4+ MBP1-11 TCR transgenic T cells treated with Prnp-siRNA. (G) Schematic of proposed mechanisms of action of PrPc in antigen-specific T cells.
###end p 70
###begin p 71
###xml 18 19 18 19 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 23 25 23 25 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;</sub>
###xml 25 27 25 27 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">11</sub>
###xml 65 71 65 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 73 77 73 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">1994</xref>
###xml 82 86 82 86 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;11</sub>
###xml 122 130 122 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 151 155 147 151 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;11</sub>
###xml 353 359 349 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Fig. 7</xref>
###xml 426 427 422 423 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 431 435 427 431 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;11</sub>
###xml 476 480 472 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 488 494 484 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Fig. 7</xref>
###xml 91 106 <span type="species:ncbi:10090">transgenic mice</span>
Next, purified CD4+ MBP1-11 TCR transgenic T cells from Lafaille et al. (1994) MBP1-11 TCR transgenic mice were activated in vitro with 2 microg/ml MBP1-11 for 72 h. The number of nonsense-siRNA-transfected T cells started to decline on Day 3 after putting the cells into culture, and none of the cells in this experimental group were viable on Day 10 (Fig. 7F). In contrast, cell numbers remained relatively stable in the CD4+ MBP1-11 TCR transgenic T cells transfected with Prnp-siRNA (Fig. 7F).
###end p 71
###begin title 72
Discussion
###end title 72
###begin p 73
###xml 48 50 48 50 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 97 98 97 98 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 224 225 224 225 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 321 322 321 322 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 385 386 385 386 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
Although it is well-known as a substrate for PrPSc in prion diseases, the normal functions of PrPc in cellular processes and non-prion CNS diseases remain enigmatic. In the EAE model of CNS autoimmunity, we describe that PrPc is an important inhibitor of peripheral immune function. Deletion, knockdown or blockade of PrPc resulted in accelerated and more severe autoimmunity while PrPc overexpression (on a PrP knockout background) resulted in diminished autoimmunity.
###end p 73
###begin p 74
###xml 53 59 53 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 61 65 61 65 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">2008</xref>
###xml 74 80 74 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 82 86 82 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">2009</xref>
###xml 264 265 264 265 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 491 492 491 492 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 645 652 645 652 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 669 670 669 670 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 677 682 677 682 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp-</italic>
###xml 782 783 782 783 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 910 914 910 914 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 1112 1113 1112 1113 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 1166 1167 1166 1167 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 1214 1219 1214 1219 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp-</italic>
###xml 1453 1454 1453 1454 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 1532 1533 1532 1533 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 165 169 <span type="species:ncbi:10090">mice</span>
###xml 1249 1253 <span type="species:ncbi:10090">mice</span>
###xml 1506 1511 <span type="species:ncbi:10090">mouse</span>
Consistent with recently published findings (Tsutsui et al., 2008; Ingram et al., 2009), we have found that EAE severity was significantly increased in PrP knockout mice. Based purely on the knockout results, however, it remained unclear whether the effects of PrPc on CNS autoimmunity were due to alterations in the susceptibility of the CNS to inflammation (i.e. neuronal survival) or due to alterations of the inflammatory response. Additionally, because the knockout animals lack all PrPc expression, it was not apparent whether alterations in immune function were due to defects in development or thymic negative selection. Pharmacological in vivo silencing of PrPc using Prnp-siRNA allowed us to define the role of this molecule more precisely in different disease stages. PrPc expression was effectively silenced solely in cells of the peripheral immune system but not brain tissue after treatment with Prnp-siRNA. In addition, Cy3-labelled siRNA was undetectable in CNS tissue indicating that the major location of siRNA knockdown is the periphery. Consequently, we conclude that the major effects of PrPc in EAE pathogenesis are based on the decrease in PrPc expression in lymphatic tissues. Furthermore, Prnp-siRNA administration in adult mice resulted in rapidly enhanced immune responses, thereby bypassing the potential for thymic defects to account for the observed exacerbated autoimmunity. Although we cannot discount the function of PrPc in the thymic maturation processes in the knockout mouse, it appears that PrPc disruption in the peripheral immune system is sufficient to enhance immune responses.
###end p 74
###begin p 75
###xml 20 21 20 21 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 180 181 180 181 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
The finding that PrPc-silencing could exacerbate disease when delivered at the time of immunization, onset of disease, or at later stages of autoimmunity strongly suggests that PrPc is an important negative regulator of T cell responses.
###end p 75
###begin p 76
###xml 12 19 12 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 70 74 70 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 174 178 174 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 286 290 286 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 487 493 487 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Fig. 5</xref>
###xml 554 558 554 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 607 614 607 614 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">323&#8211;339</sub>
###xml 636 637 636 637 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 641 642 641 642 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 701 702 701 702 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 746 753 746 753 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">323&#8211;339</sub>
###xml 848 849 848 849 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 1030 1037 1030 1037 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1080 1087 1080 1087 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">323&#8211;339</sub>
###xml 1106 1107 1106 1107 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1133 1137 1133 1137 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 1145 1151 1145 1151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Fig. 7</xref>
###xml 1179 1185 1179 1185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Fig. 7</xref>
###xml 1215 1228 1215 1228 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp in vitro</italic>
###xml 1319 1325 1319 1325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Fig. 5</xref>
###xml 156 160 <span type="species:ncbi:10090">mice</span>
###xml 713 717 <span type="species:ncbi:10090">mice</span>
Our data on in vivo T cell tracking of cells treated with fluorescent Prnp-siRNA or nonsense-siRNA strongly suggest that some of the effects we observed in mice treated with Prnp-siRNA, including the increased number of inflammatory infiltrates in the CNS, may be an indirect effect of Prnp-silencing on other lymphocyte populations, resulting in an amplification of the initial immune response. These data are complementary to observations we made in our adoptive transfer experiments (Fig. 5E, F) and in some of the survival experiments. Specifically, Prnp-siRNA or nonsense-siRNA-transfected purified OVA323-339 TCR transgenic CD45.2+ CD4+ T cells were transferred intravenously into C57BL/6 CD45.1+ wild-type mice that were immunized with OVA323-339 in complete freund's adjuvant 24 h after cell transfer to investigate whether an effect of PrPc on the survival of activated antigen-specific T cells may account for some of its effects on CNS autoimmune disease. At Day 5 post transfer, there was no difference with regard to in vivo antigen-specific proliferation between OVA323-339 TCR transgenic CD4+ T cells transfected with Prnp-siRNA (Fig. 7B), or with nonsense-siRNA (Fig. 7C). In contrast, silencing of Prnp in vitro resulted in increased proliferation of bulk T cell populations obtained from splenocytes (Fig. 5A-D).
###end p 76
###begin p 77
###xml 24 25 24 25 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 122 123 122 123 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
To study the role of PrPc as a negative regulator of T lymphocyte responses in more detail, we examined the effects of PrPc knockdown on T cell activation and survival.
###end p 77
###begin title 78
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
PrPc is a negative regulator of TCR signalling
###end title 78
###begin p 79
###xml 77 78 77 78 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 228 229 228 229 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 338 339 338 339 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
We consistently observed an increased antigen-specific proliferation when PrPc was silenced only on T cells, rather than on T cells and antigen-presenting cells. At this point, we are investigating the differential effect of PrPc silencing and overexpression on different cell types. From preliminary data it appears that silencing of PrPc in dendritic cells may be pro-apoptotic, while it is anti-apoptotic in T cells.
###end p 79
###begin p 80
###xml 333 339 333 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 341 345 341 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">1992</xref>
###xml 470 471 470 471 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 512 513 512 513 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 594 600 594 600 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 602 606 602 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">2004</xref>
TCR signalling is critical to the development of EAE at the immunization and elicitation phases of the disease. Among the earliest events of TCR engagement is recruitment of leukocyte-specific protein tyrosine kinase and subsequent phosphorylation of the TCR zeta chain. Phosphorylated zeta serves as a binding site for ZAP-70 (Chan et al., 1992), which then phosphorylates numerous substrates including linker of activated T cells. Although it is so far unclear how PrPc interacts with or influences ZAP-70, PrPc immunoprecipitated with ZAP-70 in activated T cells in a previous study (Mattei et al., 2004).
###end p 80
###begin p 81
###xml 78 79 78 79 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 141 142 141 142 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 352 353 352 353 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 366 372 366 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Fig. 6</xref>
###xml 663 669 663 669 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 671 675 671 675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">1989</xref>
###xml 693 697 693 697 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">1998</xref>
###xml 739 740 739 740 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 798 805 798 805 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 823 824 823 824 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 954 958 954 958 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;11</sub>
###xml 1000 1004 1000 1004 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 1012 1018 1012 1018 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Fig. 6</xref>
###xml 963 978 <span type="species:ncbi:10090">transgenic mice</span>
We found an increased phosphorylation of ZAP-70 in activated T cells after PrPc silencing. Suppression of the ZAP-70 dependent pathway by PrPc was confirmed by demonstrating that basal and CD3/CD28-stimulated transcription from NFAT/AP-1, two transcription factors crucial in T cell activation and differentiation, were also enhanced upon silencing PrPc in T cells (Fig. 6B). Interestingly, NFAT transcription was not altered in the PMA/ionomycin-stimulated T cells. Due to the fact that PMA/ionomycin induces NFAT/AP-1-dependent transcription by activation of protein kinase C/Ras/mitogen-activated protein kinase and calcium mobilization, respectively (Chatila et al., 1989; Liu and Heckman 1998), our results support the notion that PrPc functions as a regulator of TCR-proximal signalling. The in vivo importance of PrPc as a negative regulator of TCR signals was demonstrated by the increased incidence of spontaneous EAE in the autoimmune-prone MBP1-11 TCR-transgenic mice after treatment with Prnp-siRNA (Fig. 6C).
###end p 81
###begin p 82
###xml 28 29 28 29 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 152 159 152 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 179 183 179 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 652 656 652 656 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 735 743 735 743 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 766 767 766 767 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 854 858 854 858 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 1075 1076 1075 1076 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
We also demonstrate that PrPc may exert an indirect immunosuppressive function by promoting T cell death. Increased numbers of antigen-specific T cells in vivo after silencing of Prnp allow several explanations: (i) a decreased sequestration of these cells from secondary lymphoid organs into other compartments; (ii) a decrease of Fas-mediated apoptotic cell death; (iii) a diminished growth factor withdrawal due to decreased antigen-specific proliferation or (iv) a push of these cells into cell cycle. The latter scenario was basically ruled out by showing that there was no difference in proliferation of antigen-specific T cells transfected with Prnp-siRNA or nonsense-siRNA. Furthermore our results on increased T cell survival in vitro after silencing of PrPc strongly argue against the hypothesis of diminished growth factor withdrawal from the Prnp-siRNA-treated cells, as more cells were competing for growth factors in a closed system for a 10 day period. These results also rule out differences in tissue sequestration between the two treatment groups. Thus, PrPc may promote apoptosis in activated antigen-specific T cells, possibly mediated through a Fas pathway, or other tumor necrosis factor receptor superfamily member pathways.
###end p 82
###begin title 83
###xml 34 35 34 35 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
Summary and proposed model for PrPc
###end title 83
###begin p 84
###xml 25 26 25 26 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 189 190 189 190 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 295 296 295 296 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 318 320 318 320 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 501 502 501 502 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 783 784 783 784 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
In summary, we reveal PrPc as a molecule critically influencing T cell functions, by modulating TCR signals and limiting survival. We can thereby clearly assign an essential function to PrPc beyond being the replicative substrate or transport molecule for prions. Whether the conversion from PrPc to the infectious PrPSc conformer also involves changes in T cell function, and whether these have anything to do with prion disease mechanisms is currently unclear. It is possible that the effect for PrPc on regulating TCR signals may suggest a similar function in other cell types. Other cellular receptors, including the B cell receptor, Fc receptor, epidermal growth factor receptor and insulin receptor possess a similar signalling architecture as the TCR. Our observations put PrPc at the intersection of neuroinflammation and neurodegeneration.
###end p 84
###begin title 85
Funding
###end title 85
###begin p 86
Funding for this project was provided through a Merit Award from the Department of Veterans Affairs. Start-up Grant from the Dallas VA Research Corporation; New Investigator Award from VISN 17 from the Department of Veterans Affairs; Clinical Scientist Development Award from the Doris Duke Charitable Foundation; Merit Award from the Department of Veterans Affairs; grant from the Viragh Foundation (to Dr O.S.); grant from the VW foundation; grants from the FP6, EU Research Commission Anteprion (LSHB-CT-2006-019090) and StrainBarrier (FP6 2004 Food 3B 023183) (to C.K.); Fritz Thyssen foundation (AZ 10.08.1.178 to S.N.).
###end p 86
###begin title 87
Supplementary material
###end title 87
###begin p 88
###xml 17 22 17 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Brain</italic>
 is available at Brain online.
###end p 88
###begin title 89
Acknowledgements
###end title 89
###begin p 90
We thank Ryan Jordanhazy and Dr Paul Carson for excellent technical assistance, and Katherine Deming for critical review of the manuscript. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.
###end p 90
###begin title 91
Abbreviations
###end title 91
###begin p 92
activator protein 1
###end p 92
###begin p 93
experimental autoimmune encephalomyelitis
###end p 93
###begin p 94
enzyme-linked immunosorbent assay
###end p 94
###begin p 95
immunoglobulin G
###end p 95
###begin p 96
interleukin
###end p 96
###begin p 97
myelin basic protein
###end p 97
###begin p 98
nuclear factor of activated T cells
###end p 98
###begin p 99
phosphate buffered saline
###end p 99
###begin p 100
phorbol 12-myristate 13-acetate
###end p 100
###begin p 101
prion protein
###end p 101
###begin p 102
prion protein gene
###end p 102
###begin p 103
small interfering ribonucleic acid
###end p 103
###begin p 104
T cell receptor
###end p 104
###begin p 105
T helper cell
###end p 105
###begin p 106
zeta-chain-associated protein-70
###end p 106
###begin title 107
References
###end title 107
###begin article-title 108
###xml 53 58 <span type="species:ncbi:9606">human</span>
Differential expression of cellular prion protein on human blood and tonsil lymphocytes
###end article-title 108
###begin article-title 109
###xml 36 40 <span type="species:ncbi:10090">mice</span>
Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein
###end article-title 109
###begin article-title 110
The normal cellular prion protein is strongly expressed by myeloid dendritic cells
###end article-title 110
###begin article-title 111
Cellular isoform of the scrapie agent protein participates in lymphocyte activation
###end article-title 111
###begin article-title 112
ZAP-70: a 70 kd protein-tyrosine kinase that associates with the TCR zeta chain
###end article-title 112
###begin article-title 113
Mechanisms of T cell activation by the calcium ionophore ionomycin
###end article-title 113
###begin article-title 114
T cell Ig and mucin 1 (TIM-1) is expressed on in vivo-activated T cells and provides a costimulatory signal for T cell activation
###end article-title 114
###begin article-title 115
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
PrPc glycoform heterogeneity as a function of brain region: implications for selective targeting of neurons by prion strains
###end article-title 115
###begin article-title 116
###xml 82 87 <span type="species:ncbi:9606">human</span>
Differential constitutive and activation-dependent expression of prion protein in human peripheral blood leucocytes
###end article-title 116
###begin article-title 117
###xml 91 95 <span type="species:ncbi:10090">mice</span>
Prion protein (PrP) with amino-proximal deletions restoring susceptibility of PrP knockout mice to scrapie
###end article-title 117
###begin article-title 118
###xml 0 15 <span type="species:ncbi:10090">Transgenic mice</span>
Transgenic mice that express a myelin basic protein-specific T cell receptor develop spontaneous autoimmunity
###end article-title 118
###begin article-title 119
A role of cellular prion protein in programming T-cell cytokine responses in disease
###end article-title 119
###begin article-title 120
Akt provides the CD28 costimulatory signal for up-regulation of IL-2 and IFN-gamma but not TH2 cytokines
###end article-title 120
###begin article-title 121
A proline-rich motif in the C terminus of Akt contributes to its localization in the immunological synapse
###end article-title 121
###begin article-title 122
Both a monoclonal antibody and antisera specific for determinants unique to individual cloned helper T cell lines can substitute for antigen and antigen-presenting cells in the activation of T cells
###end article-title 122
###begin article-title 123
Prion protein induced signaling cascades in monocytes
###end article-title 123
###begin article-title 124
###xml 120 135 <span type="species:ncbi:10090">transgenic mice</span>
High incidence of spontaneous autoimmune encephalomyelitis in immunodeficient anti-myelin basic protein T cell receptor transgenic mice
###end article-title 124
###begin article-title 125
###xml 67 72 <span type="species:ncbi:9606">human</span>
The expression and potential function of cellular prion protein in human lymphocytes
###end article-title 125
###begin article-title 126
The sevenfold way of PKC regulation
###end article-title 126
###begin article-title 127
Silencing T-bet defines a critical role in the differentiation of autoreactive T lymphocytes
###end article-title 127
###begin article-title 128
###xml 8 12 <span type="species:ncbi:10090">mice</span>
129/Ola mice carrying a null mutation in PrP that abolishes mRNA production are developmentally normal
###end article-title 128
###begin article-title 129
Prion protein is a component of the multimolecular signaling complex involved in T cell activation
###end article-title 129
###begin article-title 130
Complementarity determining regions of an anti-prion protein scFv fragment orchestrate conformation specificity and antiprion activity
###end article-title 130
###begin article-title 131
###xml 54 69 <span type="species:ncbi:10090">transgenic mice</span>
Aggregate formation in the spinal cord of mutant SOD1 transgenic mice is reversible and mediated by proteasomes
###end article-title 131
###begin article-title 132
The role of the MHC class II transactivator in class II expression and antigen presentation by astrocytes and in susceptibility to central nervous system autoimmune disease
###end article-title 132
###begin article-title 133
Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity
###end article-title 133
###begin article-title 134
Leu 23 induction as an early marker of functional CD3/T cell antigen receptor triggering. Requirement for receptor cross-linking, prolonged elevation of intracellular [Ca++] and stimulation of protein kinase C
###end article-title 134
###begin article-title 135
Absence of the cellular prion protein exacerbates and prolongs neuroinflammation in experimental autoimmune encephalomyelitis
###end article-title 135
###begin article-title 136
The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease
###end article-title 136
###begin article-title 137
Perturbation of T-cell development by insertional mutation of a PrP transgene
###end article-title 137

